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ABSTRACT 
Functional overexpression of the ATP binding cassette (ABC) transporters at the 
cell surface is thought to be responsible for clinical multidrug resistance (MDR) 
in tumours of the brain. Inhibition of ABC transporters by existing inhibitors has 
proven to be inconclusive. 
 
This research program hypothesized an alternative location for the ABC 
transporters in glioblastoma cells and also proposed to develop stationary phases 
for the identification of ABC transporters inhibitors. 
 
Expression profile investigation of P-glycoprotein (PGP), multidrug resistant 
protein 1 (MRP1), multidrug resistant protein 2 (MRP2) and the breast cancer 
resistant protein (BCRP) in glioblastoma multiforme cell lines and clinical patient 
specimens suggested varying levels of expression. Localisation studies by 
confocal microscopy confirmed cell surface expression and also indicated that 
BCRP was localised at the nucleus of the T98 and LN229 cells. Immunoblots of 
LN229 nuclear extracts indicated ~ 2 fold higher expression of BCRP as 
compared to cytoplasmic extracts. Immunohistochemistry studies with clinical 
samples confirmed the nuclear and perinuclear location of BCRP. IC50 value for 
Mitoxantrone (MTX); a BCRP substrate was calculated as 0.29 ± 0.020 µM for 
the LN229 cell line, and pre-treatment with the cell impermeant fumitremorgin C 
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(FTC, 5 µM) slightly reduced the IC50 value to 0.16 ± 0.087 µM. This 
refractoriness to FTC is in contrast with the literature showing a ~ 6-fold 
reduction in IC50 value of MTX upon pre-treatment with FTC in human breast 
cancer MCF-7 cell line with ectopic expression of BCRP. The results supported 
the notion that the nuclear presence of endogenously expressed BCRP actively 
extrudes MTX, and that because FTC is not able to inhibit the nuclear BCRP, 
significant reduction in the IC50 was not observed. The results suggest that the 
treatment of clinical MDR should be expanded to include inhibition of ABC 
transporters functioning at the nuclear membrane. 
 
Cellular membrane affinity chromatography columns were developed for the 
study of the MRP1, MRP2 and BCRP using Spodoptera frugiperda (Sf9) cells 
that had been stably transfected with human Mrp1, Mrp2 or Bcrp cDNA. The 
resulting columns and a control column were characterized using frontal affinity 
chromatography using [3H]-etoposide as the marker ligand and etoposide, 
benzbromarone and MK571 as the displacers on the CMAC(Sf9MRP1) column, 
etoposide and furosemide on the CMAC(Sf9MRP2) column and etoposide and 
fumitremorgin C on the CMAC(Sf9BCRP) column. The binding affinities obtained 
from the chromatographic studies were consistent with the data obtained using 
non-chromatographic techniques and the results indicate that the immobilized 
MRP1, MRP2 and BCRP transporters retained their ability to selectively bind 
known ligands. The results indicated that the CMAC(Sf9MRP1), CMAC(Sf9MRP2) 
and CMAC(Sf9BCRP) columns can be used for the study of binding to the MRP1, 
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MRP2 and BCRP transporters and that membranes from the Sf9 cell line can be 
used to prepare CMAC columns.  
 
This study expands our knowledge of the ABC transporters and makes a case for 
the finding that nuclear efflux proteins play a pivotal role in the overall MDR 
phenotype in CNS tumours. Also the CMAC columns developed and 
characterised provide a tool to study the binding of potential therapeutic 
candidates to ABC proteins. 
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1. General Introduction 
 
1.1 Background 
 
Glioblastoma multiforme (GBM) is the most common form of malignant primary 
brain tumours in adults. Classified as a Grade IV astrocytoma, GBM develops 
from the lineage of glial cells, called astrocytes, which support nerve cells. GBM 
develops primarily in the cerebral hemispheres but can develop in other parts of 
the brain, brainstem, or spinal cord (Woodworth et al. 2013). GBM has four 
distinct genetic subtypes that respond differently to aggressive therapies, making 
treatment extremely difficult and challenging. GBM are almost always refractory 
to chemotherapy. This refraction is the result of the multi-drug resistance (MDR) 
phenotype due to the over-expression of the ATP-binding cassette (ABC) efflux 
transporters. 
 
ABC transporters are members of a protein superfamily that is one of the largest 
families of proteins. ABC transporters are trans-membrane proteins that utilize the 
energy of adenosine triphosphate (ATP) hydrolysis to carry out certain biological 
processes including translocation of various substrates across membranes (Choi, 
Yu 2013). They transport a wide variety of substrates across extra- and 
intracellular membranes, including metabolic products, lipids and sterols, and 
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drugs. Proteins are classified as ABC transporters based on the sequence and 
organization of their ATP-binding cassette (ABC) domain(s). ABC transporters 
are involved in tumour resistance, cystic fibrosis and a range of other inherited 
human. In addition to extruding a wide variety of anti-neoplastic agents, the ABC 
transporters are known to efflux a broad range of ligands like protease inhibitors 
and anti-malarial drugs, thereby decreasing their bioavailability.  
 
ABC transporters are known to play a crucial role in the development of 
multidrug resistance. In multidrug resistance, patients that are on medication 
eventually develop resistance not only to the drug they are taking but also to 
several different types of drugs. This is caused by several factors, one of which is 
increased excretion of the drug from the cell by ABC transporters. Malignant 
gliomas are frequently chemoresistant and this resistance seems to depend on 
their interaction with several ABC drug efflux transporters that are overexpressed 
by the endothelial or epithelial cells. Resistance may also involve the tumour cells 
themselves. Although ABC drug efflux transporters in tumour cells confer 
multidrug resistance (MDR) on several other solid tumours, their role in gliomas 
is unclear.  
 
Given the widespread tissue distribution and substrate recognition, it is imperative 
to investigate the role of the ABC transporters in GBM and elicit their role in 
clinical MDR. 
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1.2 Introduction to Cancer 
 
Cancer is a broad group of diseases involving unregulated cell growth. In cancer, 
cells divide and grow uncontrollably, forming malignant tumours, and invade 
nearby parts of the body. Cancer may also spread to more distant parts of the body 
through the lymphatic system or bloodstream. Not all tumours are cancerous; 
benign tumours do not invade neighbouring tissues and do not spread throughout 
the body. There are over 200 different known cancers that afflict humans. 
 
The causes of cancer are diverse, complex, and only partially understood. Many 
things are known to increase the risk of cancer, including tobacco use, dietary 
factors, certain infections, exposure to radiation, lack of physical activity, obesity, 
and environmental pollutants. These factors can directly damage genes or 
combine with existing genetic faults within cells to cause cancerous mutations. 
Approximately 5 ± 10% of cancers can be traced directly to inherited genetic 
defects. (Siegel, Naishadham & Jemal 2012) Many cancers can be prevented by 
not smoking, eating more vegetables, fruits and whole grains, eating less meat and 
refined carbohydrates, maintaining a healthy weight, exercising, minimizing 
sunlight exposure, and being vaccinated against some infectious diseases. 
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Cancer can be detected in a number of ways, including the presence of certain 
signs and symptoms, screening tests, or medical imaging. Once a possible cancer 
is detected it is diagnosed by microscopic examination of a tissue sample. Cancer 
is usually treated with chemotherapy, radiation therapy and surgery. The chances 
of surviving the disease vary greatly by the type and location of the cancer and the 
extent of disease at the start of treatment. While cancer can affect people of all 
ages, and a few types of cancer are more common in children, the risk of 
developing cancer generally increases with age. 
 
According to the epidemiological data from Cancer Research, UK it was reported 
that around 7.5 million people worldwide would die from cancer. It is believed 
that one in three people develop cancer in their lifetime. The progression of 
cancer can be described as a malignant tumour, which is the irregular and 
uncontrolled growth of cells that continually divide, then attack and damage 
surrounding tissues. The spread and growth of malignant tumours is rapid and life 
threatening if not treated in the early stages.  
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Figure 1. Stages of Carcinogenesis showing initiation, promotion, 
transformation and progression. 
 
Carcinogenesis is the term that describes the progression of cancer within the 
body. This is a multi-step process that entails mutation, amplification and deletion 
of DNA strands in essential genes of the body. There are four stages of 
carcinogenesis: initiation, promotion, transformation and progression as depicted 
in Figure 1. Initiation is the quickest and requires a carcinogen to bind to the DNA 
within the cells, resulting in damage of the strand and cause a number of 
irreversible mutations. The second stage of carcinogenesis involves amplified 
proliferation of the initiated cells. This stage of carcinogenesis can be reversed 
and occurs over many years before continuing to the final stage. Therefore the 
final stage of the progression is an extended part of the promotion stage and 
causes more proliferation. This results in an alteration of the genotype and 
phenotype of the cells causing metastasis and malignancy. The initiation of 
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carcinogenesis is due to the carcinogens, which are compounds; people are 
exposed to everyday in the environment, which modify the DNA sequences. 
(Wasserman, Zambetti & Malkin 2012) 
 
Carcinogenesis or oncogenesis or tumourigenesis is literally the creation of 
cancer. It is a process by which normal cells are transformed into cancer cells. It 
is characterized by a progression of changes at the cellular, genetic and epigenetic 
level that ultimately reprogram a cell to undergo uncontrolled cell division, thus 
forming a malignant mass. (Weber et al. 2013) 
 
Cell division is a physiological process that occurs in almost all tissues and under 
many circumstances. Under normal circumstances, the balance between 
proliferation and programmed cell death, usually in the form of apoptosis, is 
maintained by tightly regulating both processes to ensure the integrity of organs 
and tissues. Mutations in DNA that lead to cancer disrupt these orderly processes 
by disrupting the programming regulating the processes. 
 
Carcinogenesis is caused by mutation of the genetic material of normal cells, 
which upsets the normal balance between proliferation and cell death. This results 
in uncontrolled cell division and the evolution of those cells by natural selection 
in the body. The uncontrolled and often rapid proliferation of cells can lead to 
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benign tumours; some types of these may turn into malignant tumours. Benign 
tumours do not spread to other parts of the body or invade other tissues, and they 
are rarely a threat to life unless they compress vital structures or are 
physiologically active, for instance, producing a hormone. Malignant tumours can 
invade other organs, spread to distant locations and become life-threatening. 
 
More than one mutation is necessary for carcinogenesis. In fact, a series of several 
mutations to certain classes of genes is usually required before a normal cell will 
transform into a cancer cell.  
 
Cancer is fundamentally a disease of regulation of tissue growth. In order for a 
normal cell to transform into a cancer cell, genes that regulate cell growth and 
differentiation must be altered. Genetic and epigenetic changes can occur at many 
levels, from gain or loss of entire chromosomes, to a mutation affecting a single 
DNA nucleotide, or to silencing or activating a microRNA that controls 
expression of 100 to 500 genes. There are two broad categories of genes that are 
affected by these changes. Oncogenes may be normal genes that are expressed at 
inappropriately high levels, or altered genes that have novel properties. In either 
case, expression of these genes promotes the malignant phenotype of cancer cells. 
Tumour suppressor genes are genes that inhibit cell division, survival, or other 
properties of cancer cells. Tumour suppressor genes are often disabled by cancer-
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promoting genetic changes. Typically, changes in many genes are required to 
transform a normal cell into a cancer cell. 
 
There is a diverse classification scheme for the various genomic changes that may 
contribute to the generation of cancer cells. Many of these changes are mutations, 
or changes in the nucleotide sequence of genomic DNA. There are also many 
epigenetic changes that alter whether genes are expressed or not expressed. 
Aneuploidy, the presence of an abnormal number of chromosomes, is one 
genomic change that is not a mutation, and may involve either gain or loss of one 
or more chromosomes through errors in mitosis. 
 
Large-scale mutations involve the deletion or gain of a portion of a chromosome. 
Genomic amplification occurs when a cell gains many copies (often 20 or more) 
of a small chromosomal region, usually containing one or more oncogenes and 
adjacent genetic material. Translocation occurs when two separate chromosomal 
regions become abnormally fused, often at a characteristic location. A well-
known example of this is the Philadelphia chromosome, or translocation of 
chromosomes 9 and 22, which occurs in chronic myelogenous leukemia, and 
results in production of the BCR-abl fusion protein, an oncogenic tyrosine kinase. 
(Xu et al. 2012) 
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Small-scale mutations include point mutations, deletions, and insertions, which 
may occur in the promoter of a gene and affect its expression, or may occur in the 
gene's coding sequence and alter the function or stability of its protein product. 
Disruption of a single gene may also result from integration of genomic material 
from a DNA virus or retrovirus, and such an event may also result in the 
expression of viral oncogenes in the affected cell and its descendants. 
 
 
Epimutations include methylations or demethylations of the CpG islands of the 
promoter regions of genes, which result in repression or de-repression, 
respectively of gene expression. Epimutations, can also occur by acetylation, 
methylation, phosphorylation or other alterations to histones, creating a histone 
code that represses or activates gene expression, and such histone epimutations 
can be important epigenetic factors in cancer. In addition, carcinogenic 
epimutation can occur through alterations of chromosome architecture caused by 
proteins such as HMGA2 (High mobility AT hook 2). A further source of 
epimutation is due to increased or decreased expression of microRNAs 
(miRNAs). For example extra expression of miR-137 can cause downregulation 
of expression of 491 genes, and miR-137 is epigenetically silenced in 32% of 
colorectal cancers. (Sun et al. 2013) 
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Treatment options are limited owing to the nature of the disease. The progression 
is fast and the damage often irreparable. Surgical resection and radiation therapy 
are used to debulk the tumour. Once the tumour is debulked, single agent or 
adjuvant chemotherapy is employed to manage the remaining cell mass. 
 
Amongst all the malignancies, tumours of the brain are the most aggressive and 
fatal.  Owing to the fact that brain is by far the most important organ in the human 
body and is responsible for various important functions of the human body. 
 
1.2.1 Glioblastoma multiforme 
 
Tumours of the CNS are varied and include neoplasms from the neuroepithelial, 
meningeal, germ cell and sellar origins. Glioblastoma multiforme (GBM) are 
neuroepithelial tumours that result from astrocytes and/or glial cells. 
Glioblastomas are usually highly malignant ² a large number of tumour cells are 
reproducing at any given time, and they are nourished by an ample blood supply. 
Dead cells may also be seen, especially toward the centre of the tumour (Deutsch 
et al. 2013). Because these tumours come from normal brain cells, it is easy for 
them to invade and live within normal brain tissue. However, glioblastoma rarely 
spreads elsewhere in the body.  
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Because glioblastomas can grow rapidly, the most common symptoms are usually 
caused by increased pressure in the brain. These symptoms can include headache, 
nausea, vomiting, and drowsiness. Depending on the location of the tumour, 
patients can develop a variety of other symptoms such as weakness on one side of 
the body, memory and/or speech difficulties, and visual changes. For unknown 
reasons, GBM occurs more commonly in males.  
 
Most glioblastoma tumours appear to be sporadic, without any genetic 
predisposition. No links have been found between glioblastoma and smoking, 
consumption of cured meat, or electromagnetic fields. Alcohol consumption may 
be a possible risk factor. Glioblastoma has been associated with the viruses SV40 
(Simian virus 40), HHV-6 and cytomegalovirus. (Chi et al. 2012) There also 
appears to be a small link between ionizing radiation and glioblastoma. Some also 
believe that there may be a link between polyvinyl chloride and glioblastoma. 
There is an association of brain tumour incidence and malaria, suggesting that the 
anopheles mosquito, the carrier of malaria, might transmit a virus or other agent 
that could cause glioblastoma or that the immunosuppression associated with 
malaria could enhance viral replication. Also HHV-6 (Human herpesvirus 6) 
reactivates in response to hypersensitivty reactions from drugs and environmental 
chemicals. 
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1.2.1.1 Epidemiology 
 
The incidence of primary brain tumours worldwide is approximately seven per 
100,000 individuals per year, accounting for ~2% of primary tumours and 7% of 
the years of life lost from cancer before the age of 70. The malignant 
astrocytomas, the anaplastic astrocytoma and glioblastoma multiforme, are the 
most common glial tumours, with an annual incidence of 3 to 4 per 100,000 
populations. (Aldape et al. 2003) 
 
1.2.1.2 Classification 
 
Glial tumours are divided into two main categories: astrocytic and 
oligodendroglial (Benjamin, Capparella & Brown 2003). Both can be either low 
grade or high grade. High-grade (malignant) glial neoplasms can arise either alone 
(primary glioblastoma) or from a pre-existing low-grade tumour (secondary 
glioblastoma); in secondary glioblastoma, low-grade tumour may be immediately 
adjacent to highly malignant disease. All gliomas, particularly the astrocytic 
neoplasms are histologically, genetically, and therefore therapeutically 
heterogeneous (Huse, Holland 2010). 
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Glial tumours are graded pathologically, on the basis of the most malignant area 
identified, according to either the World Health Organization (WHO) system or 
the St. Anne±Mayo system, both of which are based on the presence or absence of 
nuclear atypia, mitosis, microvascular proliferation, and necrosis (Vogelstein, 
Kinzler 2004). 
 
 
Figure 2: Classification of glioblastomas 
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Gliomas can occur anywhere in the brain but usually affect the cerebral 
hemispheres. The male-to-female ratio among affected patients is about 3:2. The 
peak age at onset for anaplastic astrocytomas is in the fourth or fifth decade, 
whereas glioblastomas usually present in the sixth or seventh decade. Most 
malignant astrocytomas are sporadic, but they can occasionally complicate 
genetic syndromes such as neurofibromatosis type 1, neurofibromatosis type 2, 
Li±Fraumeni syndrome, and 7XUFRW¶VV\QGURPH (Zelcer et al. 2003). 
 
Primary glioblastomas tend to occur in older patients (mean age, 55 years), 
whereas secondary glioblastomas tend to occur in younger adults (45 years of age 
or less). The difference between these two can be recognized radiographically, 
when regions of non-enhancing tumour are evident in secondary glioblastomas, as 
well as pathologically, when a surgical specimen contains low-grade disease. The 
two types of glioblastoma arise through different molecular pathways. Primary 
glioblastomas are associated with a high rate of overexpression or mutation of the 
epidermal growth factor receptor, p16 deletions, and mutations in the gene for 
phosphatase and tensin homologues (PTEN). (Tachibana et al. 2000) 
 
 
Secondary glioblastomas have genetic alterations involving the p53 (protein 53) 
gene and overexpression of platelet-derived growth factor A and its receptor, 
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platelet-derived growth factor receptor a. These two pathways clearly demonstrate 
that the glioblastoma phenotype can arise by at least two mechanisms.  
 
1.2.1.3. Clinical presentation 
 
Brain tumours can cause either focal or generalized neurologic symptoms. 
Generalized symptoms reflect increased intracranial pressure and consist of 
headache and, when the illness is severe, nausea, vomiting, and sixth-nerve palsy. 
Focal symptoms and signs, such as hemiparesis and aphasia, reflect the 
intracranial location of the tumour. (Kleihues, Ohgaki 1999) The frequency and 
duration of symptoms vary with the type of tumour. Headache occurs in about 
half of all patients with brain tumours. Typically, the headache is diffuse, but it 
can accurately indicate the hemisphere in which the tumour is located. Generally, 
the headache is more noticeable on awakening in the morning and, even without 
treatment, dissipates within a few hours. (Han et al. 2010) The headache can 
occasionally be unilateral and throbbing and can mimic migraine or even cluster 
headaches. Seizures occur at presentation in 15 to 95 percent of patients with 
brain tumours, depending on the type of tumour. Typically, the seizures are focal 
but may become generalized and cause loss of consciousness.  
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Signs and symptoms from glioblastoma multiforme usually result from infiltration 
or compression of normal brain by tumour, oedema, and sometimes haemorrhage. 
Cerebrospinal fluid (CSF) pathways or vascular flow can also be compromised, 
leading to further deficits and increased intracranial pressure. The most common 
findings include headaches, seizures, focal neurologic deficits, and changes in 
mental status.  
 
The most common differential diagnoses include brain metastases, primary 
central nervous system lymphoma, enhancing low-grade glioma, and non-
neoplastic disorders such as abscess, multiple sclerosis, progressive multifocal 
leukoencephalopathy, cerebral infarction, and vascular malformation (Grossman, 
Batara 2004). 
 
1.2.1.4. Diagnosis 
 
The only test needed to diagnose a brain tumour is cranial magnetic resonance 
imaging (MRI). Computed tomography (CT) can miss structural lesions, 
particularly in the posterior fossa, or non-enhancing tumours such as low-grade 
gliomas. Therefore, if a brain tumour is a diagnostic consideration, MRI with 
gadolinium enhancement is the test of choice; a normal contrast-enhanced MRI 
scan essentially rules out the possibility of a brain tumour. An angiogram can also 
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be employed where a special dye is injected into the arteries that feed the brain, 
making the blood vessels visible on X-ray. This test helps locate blood vessels in 
and around the brain tumour. Biopsy where a surgeon typically removes a small 
tissue sample from the tumour to further study the type of the tumour is used a 
confirmatory procedure. (Gajewicz et al. 2003) 
 
1.2.1.5. Pathogenesis 
 
At least two distinct molecular pathways lead to the development of glioblastoma 
multiforme. When this tumour arises from a pre-existing low-grade astrocytoma, 
it is referred to as a secondary glioblastoma. The low-grade astrocytomas often 
have mutations in the p53 tumour-suppressor gene and overexpression of platelet-
derived growth factor (PDGF).  
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Figure 3. Pathogenesis of glioblastomas 
 
Primary glioblastomas demonstrate loss of the tumour-suppressor gene PTEN or 
amplification or overexpression of epidermal growth factor receptor (EGFR) 
without p53 mutation (Grossman, Batara 2004). Multiple theories about the 
pathogenesis of gliomas exist as shown in Figure 3. Astrocytes arising from glial 
progenitor cells that morph from neural stem cells result in homogenous tumour 
bulk. Neural stem cells may also mutate into tumour initiating cells as shown in 
C.) Tumour initiating cells may also result from progenitor cells as well as 
dedifferentiated glial cells. 
 
52 
 
1.2.1.6. Treatment 
 
There are no curative treatment options for GBM. The standard approach is to 
surgically resect the tumour as much as possible. Surgery has a critical role in the 
management of patients with newly diagnosed glioblastoma multiforme. 
Stereotactic biopsies are generally reserved for tumours located in deep tissue or 
in patients with extensive lesions where meaningful debulking cannot be 
obtained. Surgical resection is followed by radiotherapy. Radiation remains the 
most effective therapy for post-operative patients with glioblastoma multiforme. 
One of the recent advanced surgical techniques is gamma knife radio surgery and 
stereotactic radiosurgery using cyberknife or other linear accelerator based 
systems. 
 
 
 
 
Figure 4. Structure of Temozolamide; a chemotherapeutic agent for the 
treatment of gliomas 
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Figure 5. Structure of Nitrosourea; used in chemotherapy of gliomas 
 
 
Chemotherapy is often administered in an adjuvant therapy to patients who have 
no remaining detectable cancer but are at high risk for recurrence. In this 
situation, the impact of chemotherapy is optimized till the total-body tumour 
burden is minimal. However effective chemotherapy is limited due to drug 
resistance. Nitrosoureas are used to manage newly diagnosed GBM. Recently 
temozolomide has been used as the primary choice of treatment, as it was shown 
to significantly improve the survival from 12.1 months to 14.6 months (Du, Searle 
2009). 
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1.2.2. Multidrug resistance 
 
The phenomenon where cells become resistant to structurally unrelated drugs is 
classically termed as multi drug resistance (MDR) (Lemos et al. 2009). MDR can 
be innate or acquired during chemotherapy. 
 
There are two general classes of resistance to anticancer drugs: those that impair 
delivery of anticancer drugs to tumour cells and those that arise in the cancer cell 
itself due to genetic and epigenetic alterations that affect drug sensitivity. 
Impaired drug delivery can result from poor absorption of orally administered 
drugs, increased drug metabolism or increased excretion, resulting in lower levels 
of drug in the blood and reduced diffusion of drugs from the blood into the 
tumour mass. Recent studies have emphasized the importance of the tumour 
vasculature and an appropriate pressure gradient for adequate drug delivery to the 
tumour (Liu et al. 2009). In addition, some cancer cells that are sensitive to 
chemotherapy as monolayer cells in culture become resistant when transplanted 
into animal models. This indicates that environmental factors, such as the 
extracellular matrix or tumour geometry, might be involved in drug resistance 
(Decleves et al. 2006).  Cancer cells grown in culture as three-dimensional 
spheroids, mimicking their in vivo geometry, have also been shown to become 
resistant to cancer drugs.  
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Cellular mechanisms of drug resistance have been intensively studied, as 
experimental models can be easily generated by in vitro selection with cytotoxic 
agents. Cancer cells in culture can become resistant to a single drug, or a class of 
drugs with a similar mechanism of action, by altering the drug's cellular target or 
by increasing repair of drug-induced damage, frequently to DNA (Decleves et al. 
2006). After selection for resistance to a single drug, cells might also show cross-
resistance to other structurally and mechanistically unrelated drugs. This might 
explain why treatment regimens that combine multiple agents with different 
targets are not more effective. 
 
Multidrug resistance can also result from activation of co-ordinately regulated 
detoxifying systems, such as DNA repair and the cytochrome P450 mixed-
function oxidases (Dauchy et al. 2008).  
 
Resistance can also result from defective apoptotic pathways. This might occur as 
a result of malignant transformation; for example, in cancers with mutant or non-
functional p53 (Huang et al. 2009). Alternatively, cells might acquire changes in 
apoptotic pathways during exposure to chemotherapy, such as alteration of 
ceramide levels or changes in cell-cycle machinery, which activate checkpoints 
and prevent initiation of apoptosis (Liu et al. 2008). 
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An important principle in multidrug resistance is that cancer cells are genetically 
heterogeneous (Boutin et al. 2009). Although the process that results in 
uncontrolled cell growth in cancer favours clonal expansion, tumour cells that are 
exposed to chemotherapeutic agents will be selected for their ability to survive 
and grow in the presence of cytotoxic drugs (Calcagno et al. 2010). These cancer 
cells are likely to be genetically heterogeneous because of the mutator phenotype. 
So, in any population of cancer cells that is exposed to chemotherapy, more than 
one mechanism of multidrug resistance can be present. This phenomenon has 
been called multifactorial multidrug resistance. 
 
Finally, one of the main reasons of the MDR phenotype is the over-expression of 
the ATP-binding cassette efflux transporters. 
 
ABC transporters are known to play a crucial role in the development of 
multidrug resistance (MDR). In MDR, patients that are on medication eventually 
develop resistance not only to the drug they are taking but also to several different 
types of drugs. This is caused by several factors, one of which is increased 
excretion of the drug from the cell by ABC transporters. For example, the ABCB1 
protein (P-glycoprotein) functions in pumping tumour suppression drugs out of 
the cell. Pgp also called MDR1, ABCB1, is the prototype of ABC transporters and 
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also the most extensively-studied gene. Pgp is known to transport organic cationic 
or neutral compounds. A few ABCC family members, also known as MRP, have 
also been demonstrated to confer MDR to organic anion compounds. The most-
studied member in ABCG family is ABCG2, also known as BCRP (breast cancer 
resistance protein) confer resistance to most of Topoisomerase I or II inhibitors 
such as topotecan, irinotecan, and doxorubicin. 
 
It is unclear exactly how these proteins can translocate such a wide variety of 
drugs, however one model (the hydrophobic vacuum cleaner model) states that, in 
P-glycoprotein, the drugs are bound indiscriminately from the lipid phase based 
on their hydrophobicity. 
 
 
1.2.3. ATP binding cassette transporters 
 
The ATP-binding cassette (ABC) superfamily of proteins contains a number of 
membrane bound ATP driven transporters that pump drugs, drug metabolites and 
endogenous compounds out of cells (Liu et al. 2009). Although at present there 
are 49 known human ABC family members belonging to 7 different subfamilies; 
P-glycoprotein (Pgp), multi drug resistance protein 1 (MRP1), multi drug 
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resistance protein 2 (MRP2) and the breast cancer resistant protein (BCRP) have 
gained significant attention, owing to their widespread tissue distribution and role 
in multiple drug resistance. 
 
 
 
 
 
 
 
 
 
Figure 6. A typical ABC protein containing two transmembrane domains 
70'V (DFK GRPDLQ FRQVLVWLQJ RI Į-helices which 'criss cross' the 
phospholipid bilayer, forming between between six to eleven (usually six), 
membrane-spanning regions. All ABC proteins also contain either two ATP-
binding domain(s), which are also called nucleotide-binding domains (NBDs) 
and are located on the cytoplasm side of the phospholipid bilayer. 
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ABCs are mostly unidirectional, meaning they only function in one direction. In 
bacteria, they mainly pump essential compounds such as sugars, vitamins, metal 
ions, etc. into the bacteria. These transporters are called importers. In eukaryotes, 
ABCs mainly move compounds from within the cytoplasm to the outside of the 
cell or into a membrane bound organelle (endoplasmic reticulum, mitochondria, 
peroxisomes, etc.). These transporters are called exporters. ABC transporters are 
largely dispersed throughout the genome and have an extremely wide variety of 
uses. For example lipid flippases work by flipping a lipid from the inner 
phospholipid membrane to the other phospholipid membrane. 
 
ABC transporters utilize the energy of ATP hydrolysis to transport various 
substrates across cellular membranes. They are divided into three main functional 
categories. In prokaryotes, importers mediate the uptake of nutrients into the cell. 
The substrates that can be transported include ions, amino acids, peptides, sugars, 
and other molecules that are mostly hydrophilic. The membrane-spanning region 
of the ABC transporter protects hydrophilic substrates from the lipids of the 
membrane bilayer thus providing a pathway across the cell membrane. 
Eukaryotes do not possess any importers. (Gottesman, Pastan 1993) Exporters or 
effluxers, which are both present in prokaryotes and eukaryotes, function as 
pumps that extrude toxins and drugs out of the cell. In gram-negative bacteria, 
exporters transport lipids and some polysaccharides from the cytoplasm to the 
periplasm. The third subgroup of ABC proteins do not function as transporters, 
but are rather involved in translation and DNA repair processes. 
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The common feature of all ABC transporters is that they consist of two distinct 
domains, the transmembrane domain (TMD) and the nucleotide-binding domain 
(NBD). The TMD, also known as membrane-spanning domain (MSD) or integral 
membrane (IM) domain, consists of alpha helices, embedded in the membrane 
bilayer. It recognizes a variety of substrates and undergoes conformational 
changes to transport the substrate across the membrane. The sequence and 
architecture of TMDs is variable, reflecting the chemical diversity of substrates 
that can be translocated. The NBD or ATP-binding cassette (ABC) domain, on the 
other hand, is located in the cytoplasm and has a highly conserved sequence. The 
NBD is the site for ATP binding. In most exporters, the N-terminal 
transmembrane domain and the C-terminal ABC domains are fused as a single 
polypeptide chain, arranged as TMD-NBD-TMD-NBD. An example is the E. coli 
hemolysin exporter HlyB. Importers have an inverted organization, that is, NBD-
TMD-NBD-TMD, where the ABC domain is N-terminal whereas the TMD is C-
terminal, such as in the E. coli MacB protein responsible for macrolide resistance. 
 
The structural architecture of ABC transporters consists minimally of two TMDs 
and two ABCs. Four individual polypeptide chains including two TMD and two 
NBD subunits may combine to form a full transporter such as in the E. coli 
BtuCD importer involved in the uptake of vitamin B12. Most exporters, such as in 
the multidrug exporter Sav1866 from Staphylococcus aureus, are made up of a 
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homodimer consisting of two half transporters or monomers of a TMD fused to a 
nucleotide-binding domain (NBD). (Dawson, Locher 2007) A full transporter is 
often required to gain functionality. Some ABC transporters have additional 
elements that contribute to the regulatory function of this class of proteins. In 
particular, importers have a high-affinity binding protein (BP) that specifically 
associates with the substrate in the periplasm for delivery to the appropriate ABC 
transporter. Exporters do not have the binding protein but have an intracellular 
domain (ICD) that joins the membrane-spanning helices and the ABC domain. 
The ICD is believed to be responsible for communication between the TMD and 
NBD. 
 
1.2.3.1. P-glycoprotein  
 
Pgp was discovered by Juliano and Ling (Tolcher et al. 1996) and is possibly the 
best-studied ABC drug efflux transporter to date. Its most striking property is the 
diversity in structure of substrates that can be transported, including a vast 
number of drugs applied for a range of therapeutic applications. Many cytotoxic 
anticancer drugs are transported by Pgp, which was first identified because it was 
overexpressed in cell lines made resistant to such cytotoxic drugs (Tolcher et al. 
1996). Owing to the broad substrate specificity of Pgp, the cells displayed cross-
resistance to many different cytotoxic drugs, hence the name multidrug resistance. 
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There are few common structural denominators for transported Pgp substrates. 
They are usually organic molecules ranging in size from less than 200 Da to 
almost 1900 Da. Many contain aromatic groups, but non-aromatic linear or cyclic 
molecules are also transported. Most of the efficiently transported molecules are 
uncharged or basic in nature, but some acidic compounds can also be transported 
(Teodori et al. 2006). The only common denominator identified so far in all Pgp 
substrates is their amphipathic nature (Lee et al. 2002). This may have to do with 
the mechanism of drug translocation by Pgp: it has been proposed that 
intracellular Pgp substrates first have to insert into the inner hemi-leaflet of the 
FHOOPHPEUDQHEHIRUHEHLQJµIOLSSHG¶WRWKHRXWHUKHPLOHDIOHWRUEHLQJH[WUXGHG
directly into the extracellular medium by Pgp. Only amphipathic molecules would 
have the proper membrane insertion properties (Teodori et al. 2006). 
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Figure 7. Structure of Pgp 
 
 
As most Pgp substrates are quite hydrophobic, in principle they can diffuse 
passively across biological membranes at a reasonable rate. For cell-biological 
and pharmacological studies, this means that in the absence of active transport, 
Pgp substrates will cross membranes and penetrate into tissues and 
pharmacological compartments. It also means that a contribution of active 
transport by Pgp will only result in noticeable distribution effects if the rate of 
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active transport for a certain compound is substantial relative to the passive 
diffusion rate. If not, the pump activity will be overwhelmed by the passive 
diffusion component. 
 
1.2.3.1.1. Inhibitors of Pgp 
 
Certain compounds can also inhibit transport of cytotoxic and other substrates by 
Pgp. Many of the initially identified inhibitors, like the calcium channel blocker 
verapamil or the immunosuppressive agent cyclosporin A, turned out to be 
themselves transported substrates of Pgp, suggesting that they act as competitive 
inhibitors (Rao, Scarborough 1994). 
 
 
 
 
 
 
Figure 8. Structure of Verapamil 
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Initial thoughts on clinical application of Pgp inhibitors were focused on reversing 
MDR in chemotherapy-resistant tumour cells that contain significant amounts of 
Pgp, but later findings indicated that such inhibitors might also be useful to 
modulate the general pharmacological behaviour of drugs in the body. The Pgp 
inhibitors that were initially recognized, such as verapamil, are actually relatively 
poor Pgp inhibitors in vivo, and they frequently have their own pharmacodynamic 
effects that put severe restrictions on the plasma levels that can be safely achieved 
in patients (Iannetti, Spalice & Parisi 2005). 
 
 
 
 
 
PSC 833 is a cyclosporin A analogue that does not have the immunosuppressive 
effect of cyclosporin A, and can be given at quite high dosages to patients and 
(Chen et al. 1997). PSC 833 is a high-affinity, but slowly transported substrate for 
Pgp, which probably acts as an effective inhibitor because its release from Pgp is 
very slow. Although PSC 833 is an efficient Pgp inhibitor, it does have the 
complication that it is also an inhibitor of cytochrome P450 3A4 (CYP3A4), one 
of the main drug-metabolizing enzymes in the body. Consequently, when 
administered to patients, next to inhibiting Pgp, it may have additional effects on 
the clearance of drug substrates that are degraded by CYP3A4. Many cytotoxic 
anticancer drugs that are Pgp substrates, such as etoposide and doxorubicin, are 
also extensively degraded by CYP3A4. Therefore, co-administration with PSC 
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833 can intensify the toxic side effects of these anticancer drugs, necessitating a 
dose reduction for safe treatment of the patient. The main dose-limiting toxicity of 
PSC 833 itself in patients is ataxia (Evers et al. 2000), (Baer et al. 2002), (Kolitz 
et al. 2004).  
 
 
 
 
 
 
 
Figure 9: Structure of Cyclysporine A 
 
 
LY335979 is another specifically developed, highly effective Pgp inhibitor 
(Dantzig et al. 1996). Like PSC-833, it improves chemotherapy response in mice 
with transplanted Pgp-containing tumours, and it does not clearly affect the 
plasma clearance of intraperitoneally administered doxorubicin or etoposide. 
However, this was only tested with intravenously or intraperitoneally 
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administered LY335979. Whether LY335979 could be orally active is as yet 
unclear (Dantzig et al. 1999). 
 
1.2.3.1.2. Functions of Pgp 
 
Pgp is mainly present in epithelial cells in the body, where it localizes to the 
apical membrane (Evers et al. 1996). As a consequence, transported Pgp 
substrates are translocated from the basolateral to the apical side of the 
epithelium. This can have dramatic consequences for the pharmacological 
behaviour of substrate drugs.  
 
1.2.3.1.3. Role in blood brain barrier 
 
Endothelial cells of the small blood capillaries in the brain are closely linked to 
each other by tight junctions, and they cover the entire wall of these blood vessels. 
As a consequence, all compounds that are not small enough to diffuse between the 
cells have to cross the endothelial cell in order to translocate from the blood 
compartment into the surrounding brain tissue. Since most Pgp substrates are 
quite hydrophobic, in principle they have the possibility to passively diffuse 
across the endothelial cell membranes and thus enter the brain at a reasonable 
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rate. However, owing to a high level of Pgp in the luminal membrane of the 
endothelial cells (Zhang et al. 2004) substrate drugs entering the endothelial cells 
from the blood are immediately pumped back into the blood. As a consequence, 
the net penetration of substrate drugs and other substrate compounds from the 
blood into the brain tissue can be dramatically decreased. In the absence of Pgp in 
the blood±brain barrier, the brain penetration of Pgp substrate drugs can increase 
up to 10- to 100-fold, with sometimes dramatic consequences for the clinical 
applicability and toxicity of compounds. 
 
The brain is a critical organ, and potentially very sensitive to all kinds of toxic and 
other pharmacodynamic actions of exogenous compounds. It is quite obvious that 
Pgp must have evolved in part to protect the brain from damaging effects of 
xenotoxins that can be taken up with food, or are perhaps generated by pathogenic 
organisms in the intestine.  
 
1.2.3.1.4. Role in excretion 
 
Pgp is very abundant in the bile canalicular membrane of hepatocytes, and in the 
apical membrane of small and large intestinal epithelium (Chieli et al. 1993). One 
function for Pgp in these locations is extrusion of substrate drugs and other 
compounds from the liver hepatocyte into the bile, and from the intestinal 
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epithelium into the intestinal lumen. As many compounds can readily enter the 
hepatocytes and intestinal epithelial cells from the blood compartment, this would 
result in a net excretory function for Pgp. Extruded substrates would ultimately 
leave the body via the faeces, so overall this would result in plasma clearing and 
detoxifying function.  
 
1.2.3.1.5. Role in oral drug bioavailability 
 
As Pgp is abundant in the intestinal epithelium, one obvious potential function is 
that it could restrict the rate at which substrate compounds present in the intestinal 
lumen enter the bloodstream. Many drugs are Pgp substrates, so this could mean 
that Pgp might restrict the bioavailability of many orally administered drugs. In 
Pgp knockout animals, the oral bioavailability of the anticancer drug paclitaxel 
was markedly increase. Later experiments by various groups confirmed that the 
oral bioavailability of many other drugs is limited by Pgp activity as well. For 
pharmacotherapy purposes, oral bioavailability is a very important factor. Oral 
drug administration is highly preferred because it is cheap, relatively safe, and 
patient friendly. However, if a drug has low oral bioavailability, the plasma level 
of the drug may not attain sufficiently high levels to have therapeutic effect. Also, 
low drug bioavailability is frequently associated with variable drug uptake, and 
this can be a problem if the drug has a narrow therapeutic concentration window. 
Thus, Pgp activity can be a major problem for therapeutic applications of drugs. 
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For this reason, it is of interest for pharmaceutical companies to check at an early 
stage whether a drug under development is a good Pgp substrate, because this 
could mean that it is not readily orally available. Depending on the therapeutic 
category of the drug this could limit its ultimate clinical use. 
 
1.2.3.1.6. Role in pharmacotherapy 
 
Because of the impact of Pgp on a variety of important pharmacological and 
toxicological processes, it is of great interest to consider whether the available 
efficient Pgp inhibitors could be used to optimize various aspects of 
pharmacotherapy. Efforts to increase the penetration of anticancer drugs into 
multidrug resistant tumours containing Pgp is a very important aspect, especially 
in chemotherapy treatment of tumours like GBM that are positioned behind the 
blood±brain barrier, and therefore poorly accessible to most anticancer drugs. For 
other diseases of the central nervous system (CNS) it might be desirable to 
improve the brain parenchyme penetration of drugs. As a proof of principle to 
show that it is possible to extensively inhibit Pgp in the blood±brain barrier, a 
number of studies were performed. Indeed, it turned out to be feasible to largely 
block Pgp in the blood±brain barrier in mouse models, but only when highly 
efficacious Pgp inhibitors were used (Hopper et al. 2001), (Stouch, Gudmundsson 
2002), (Ekins et al. 2000).  
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1.2.3.2. Multidrug resistant protein 1 
 
MRP1 was first identified in a cell line made highly resistant to doxorubicin and 
subsequent analysis showed that it conferred MDR against a range of anticancer 
drugs (Hidalgo, Li 1996). Substrate anticancer drugs include Vinca alkaloids, 
anthracyclines, epipodophyllotoxins, mitoxantrone and methotrexate. Unlike Pgp, 
MRP1 does not confer high levels of resistance to paclitaxel or bisantrene in cells. 
In further contrast to Pgp, MRP1 functions mainly as a co-transporter of 
amphipathic organic anions. It can transport hydrophobic drugs or other 
compounds that are conjugated or complexed to the anionic tripeptide glutathione 
(GSH), to glucuronic acid, or to sulphate (Spiegl-Kreinecker et al. 2002). In fact, 
efficient export of several non-anionic anticancer drugs by MRP1 is dependent on 
a normal cellular supply of GSH (van Asperen et al. 1997), and it is likely that 
MRP1 exports drugs such as vincristine and etoposide by co-transport with 
reduced GSH (Ozben 2006), (Jungsuwadee et al. 2009). Non-organic heavy 
metals like arsenite and trivalent antimony are also transported by MRP1, in all 
likelihood complexed to GSH (van Zanden et al. 2007).  
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Figure 10. Structure of MRP 1. The upper line indicates the arrangement of 
domains of MRP1 (L0 indicates the cytoplasmic loop connecting TMD0 and 
TMD1; ABC-N and ABC-C indicate the cytoplasmic ABC domains at the N- 
and the C-half of protein respectively). Arrows indicate cleavage at Site I, Site 
II and Site III at which Vi-induced cleavage reactions generate fragments of 95 
kDa (f95), 85 kDa (f85) and 25 kDa (f25) respectively. Half-shaded regions of 
the polypeptide chain denotes the conserved Walker A and Walker B motifs, 
shaded regions show the ABC-signature motifs.  
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In contrast to Pgp, MRP1 localizes to the basolateral membrane of epithelial cell 
layers, and its substrates are therefore transported towards the basolateral side of 
epithelia. Knockout mice lacking Mrp1 are viable and fertile, but they do show 
deficiencies in LTC4-mediated inflammatory reactions, suggesting that secretion 
of LTC4 is an important physiological function of MRP1 (Boumendjel et al. 
2005), (Wu et al. 2005). 
 
1.2.3.2.1. Pharmacological functions of Multidrug resistant protein 1 
 
Even though MRP1 localises predominantly to the basolateral membrane of 
epithelial cells, it still has important pharmacological and toxicological functions. 
Wijnholds et al. showed that Mrp1 knockout mice are more sensitive to the 
toxicity of intravenously administered etoposide in the oropharyngeal mucosal 
layer and testicular tubules (Wijnholds et al. 2000). This can be explained by the 
fact that these cells are shielded from blood-borne toxins by epithelia that have 
the basolateral membrane facing the blood circulation. Moreover, Mrp1 in the 
basolateral membrane of choroid plexus epithelial cells can mediate a substantial 
clearance of etoposide from the cerebrospinal fluid, indicating that this 
compartment is also protected by Mrp1 (Filipits et al. 2005). Other studies 
demonstrated that a combined deficiency of Mdr1a and Mdr1b, Pgps and Mrp1 in 
knockout mice resulted in a dramatically increased sensitivity to intraperitoneally 
administered vincristine, but also to etoposide, whereas a Pgp deficiency alone 
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resulted in a 16- and 1.75-fold increased sensitivity to this drug, respectively 
(Meaden et al. 2002). In this case, greatly increased vincristine toxicity was 
observed in bone marrow and the gastrointestinal mucosa, suggesting that these 
compartments are normally extensively protected by the Pgp and/or Mrp1 
transporters. 
 
At the cellular level, the endogenous expression of MRP1 can already contribute 
substantially to the basal resistance of cell lines to a range of cytotoxic anticancer 
drugs, as was demonstrated in vitro with murine fibroblast and embryonic stem 
cell lines deficient for murine Mrp1 and/or Mdr1a and Mdr1b (Deeley, Cole 
1997). A marked increase in sensitivity to epipodophyllotoxins, vinca alkaloids, 
anthracyclines, topotecan, SN-38, and arsenite was found in these lines due to 
Mrp1 deficiency. Such contributions can explain the markedly increased drug 
sensitivity of bone marrow and intestinal epithelial cells deficient for Mrp1, and 
especially when drug-transporting Pgp is also absent. 
 
1.2.3.2.2. Inhibitors of Multidrug resistant protein 1 
 
So far, it has been much more difficult to find good small molecule inhibitors for 
MRP1 than for Pgp, especially ones that work in intact cells. This probably has to 
do with the preference of MRP1 for anionic compounds as substrates and 
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inhibitors: most anionic compounds enter cells poorly, so it may be difficult to 
obtain sufficient intracellular concentrations of the inhibitor for efficacious 
inhibition. A variety of inhibitors of MRP1 have been described. Some examples 
are the LTC4 analogue MK571, LTC4 itself, S-decylglutathione, sulfinpyrazone, 
benzbromarone and probenecid (Boumendjel et al. 2005), (Bakos et al. 2000), 
(Bakos et al. 1998).  
 
Figure 11: Structure of MK571, an inhibitor of MRP1. 
 
Pgp inhibitors like cyclosporin A and PSC 833, with reasonable cellular 
penetration, inhibit MRP1, but only with low affinity and poor specificity (Qadir 
et al. 2005). For specific in vivo inhibition of MRP1 the general organic anion 
transporter inhibitors sulfinpyrazone, benzbromarone and probenecid are also not 
very suitable, as they extensively affect organic anion uptake systems as well 
(Bobrowska-hgerstrand et al. 2003), (Norman 1998). Moreover, these 
compounds need to be used at relatively high concentrations. For the aim of 
specifically inhibiting MRP1 activity in vivo, for instance to improve anticancer 
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chemotherapy, better MRP1 inhibitors will have to be developed, with reasonable 
specificity and cellular penetration properties, and low cytotoxicity. 
 
1.2.3.3. Multidrug resistant protein 2 
 
The in vivo function of MRP2 was well studied before the identification of the 
MRP2 gene, as the MRP2 gene is fully deficient in two mutant rat strains 
75í*< DQG (+%5 DQG LQ SDWLHQWV WKDW VXIIHU IURP WKH 'XELQ±Johnson 
syndrome (Hashimoto et al. 2002). Affected individuals suffer from a recessively 
inherited conjugated hyperbilirubinemia, which can result in observable jaundice, 
but overall the clinical phenotype of this disease is relatively mild. The cause of 
the defect is the absence of MRP2 from the hepatocyte canalicular membrane, 
where it normally mediates the hepatobiliary excretion of mono- and bis-
glucuronidated bilirubin. The MRP2 gene was identified based on its similarity to 
MRP1, and absence of its expression in MRP2-deficient rats and humans (Evers 
et al. 1998). 
 
Identification of substrates transported by MRP2 was based on many different 
approaches: analysis of compounds transported into bile of normal rats, but not of 
Mrp2 mutant rats; differential uptake of compounds into inside-out bile 
canalicular membrane vesicles isolated from normal and Mrp2 mutant rats; 
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transfection or transduction of human MRP2 or rat or rabbit Mrp2 cDNA into cell 
lines followed by analysis of drug resistance, accumulation of compounds into 
cells or isolated inside-out membrane vesicles, and transepithelial transport of 
compounds. In one study an MRP2 cDNA antisense construct was used to 
suppress endogenous MRP2 levels in the HEPG2 hepatocyte cell line (Morrow, 
Smitherman & Townsend 2000). It turns out there are many similarities between 
the compounds transported by MRP2 and MRP1, but there is not a complete 
overlap. Anticancer drugs transported by MRP2 include methotrexate, 
doxorubicin, epirubicin, mitoxantrone, vincristine, vinblastine, CPT-
11/irinotecan, SN-38, cisplatin and etoposide (Klopman, Shi & Ramu 1997), 
(Evers et al. 2000), (Tada et al. 2002), (Vlaming et al. 2006). Like MRP1, MRP2 
is primarily an organic anion transporter, so it seems likely that weakly basic 
drugs are co-transported with GSH by MRP2. This was strongly suggested by a 
study of vinblastine transport in MRP2-transduced polarized cells, which occurs 
stoichiometrically with GSH transport. Moreover, depletion of cellular GSH by 
treatment with l-buthionine sulfoximine (l-BSO) resulted in decreased substrate 
transport and drug resistance in MRP2-overexpressing cells (Liu et al. 2001). 
Mrp2 is involved in the hepatobiliary excretion of GSH conjugates of inorganic 
arsenic, after administration of arsenite (H3AsO3) to rats (Kala et al. 2000). 
MRP2 (and probably MRP1) may therefore also be involved in cellular and 
organismal protection against arsenic trioxide (As2O3), a compound recently 
introduced for the treatment of relapsed acute promyelocytic leukemia by 
extrusion of As-GSH conjugates. The observation that cellular GSH levels 
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correlate inversely with the sensitivity to arsenic trioxide is in line with this 
possibility, although direct detoxification of As by GSH complexation may be as 
relevant (Liu et al. 2001). 
 
Other well-defined substrates of MRP2 include many amphipathic anionic drugs 
and endogenous compounds, including GSH-, glucuronide-, and sulfate 
conjugates. Some examples are reduced and oxidized GSH, LTC4, LTD4, LTE4, 
estradiol-ȕȕ-d-glucuronide) (E217G), p-aminohippurate, S-glutathionyl 2,4-
dinitrobenzene (GS-DNP), (S-glutathionyl-)sulfobromophthalein, glucuronidated 
SN-38, pravastatin, and the organic anion transport inhibitor sulfinpyrazone. 
Moreover, some food-derived (pre-) carcinogens and glucuronide conjugates 
thereof are also transported by Mrp2 (Cui et al. 1999), (Morikawa et al. 2000), 
(Horikawa et al. 2002), (Huisman et al. 2002). 
 
1.2.3.3.1. Pharmacological functions of Multidrug resistant protein 2 
 
Unlike MRP1, but similar to Pgp, MRP2 localizes to the apical membrane of 
polarized cell lines in which it is expressed (Nies et al. 1998). Moreover, in vivo 
MRP2 is found in a range of tissues important for the pharmacokinetics of 
substrate drugs, namely, next to the bile canalicular membrane of hepatocytes in 
the luminal membrane of the small intestinal epithelium and in the luminal 
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membrane of the proximal tubules of the kidney (Dresser, Leabman & Giacomini 
2001), (Harris et al. 2001). In human jejunum, MRP2 mRNA levels as measured 
by RT-PCR were amongst the highest of all tested ABC transporters (Berggren et 
al. 2007). 
 
The role of MRP2 in hepatobiliary excretion has been amply demonstrated, but 
MRP2 in intestine and kidney could also contribute to direct intestinal and active 
renal excretion of substrate compounds, and intestinal MRP2 could limit oral 
uptake of compounds.  
 
In humans MRP2 has been detected in the apical syncytiotrophoblast membrane 
of term placenta (Meyer zu Schwabedissen et al. 2005). Similar to Pgp present at 
these locations, MRP2 might limit the brain and foetal penetration of a range of 
substrate compounds present in the maternal plasma. Overall, there is fairly 
extensive overlap between MRP2 and Pgp tissue distribution, so it is likely that 
these two proteins have considerable overlap in pharmacological and 
toxicological protective functions, although with different sets of substrates. 
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1.2.3.3.2. Inhibitors of Multidrug resistant protein 2 
 
The selection of currently available small molecule inhibitors of MRP2 that can 
be used in intact cells is quite limited. Many of the anionic transported substrates 
of MRP2 act as competitive inhibitors when applied in in vitro systems where 
MRP2 is present in an inside-out orientation. Some examples are LTC4, 
phenolphtalein glucuronide and fluorescein methotrexate (Gutmann et al. 2000), 
(Ogasawara, Takikawa 2001), (Breen et al. 2004). However, such compounds 
frequently do not penetrate most normal cells to a sufficient extent to obtain 
useful levels of inhibition. MRP2 inhibitors that have been demonstrated to work 
to a greater or lesser extent in intact cells include cyclosporin A, sulfinpyrazone, 
benzbromarone, probenecid, PSC 833, PAK-104P and furosemide (Westley et al. 
2006), (Bakos et al. 2000), (Chen et al. 2003). It is clear that compounds that 
specifically inhibit MRP2 are rare, as all the compounds identified so far have 
considerable activity against MRP1 and Pgp. 
 
1.2.3.4. Breast Cancer Resistant Protein  
 
Breast cancer resistant protein (BCRP) was first discovered in a doxorubicin-
resistant MCF-7 breast cancer cell line (MCF-7/AdrVp) (Doyle et al. 1998). 
Transfection of BCRP cDNA demonstrated that BCRP itself could confer 
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resistance to mitoxantrone, doxorubicin and daunorubicin, and that it acted by 
energy-dependent extrusion of its drug substrates (Gupta et al. 2006). Because the 
gene was isolated from a breast cancer cell line, it was called the breast cancer 
resistance protein BCRP. BCRP cDNA sequences were also cloned by Miyake et 
al. (Miyake et al. 1999) and Allikmets et al. (Allikmets et al. 1998), who called 
the gene MXR (mitoxantrone resistant receptor) and ABCP (placental ABC 
protein), respectively.  
 
 
 
 
 
 
 
Figure 12. Structure of BCRP consists of two half-transporters. It is proposed 
that the transmembrane domains form a channel-like structure serving to 
translocate substrates. TM = transmembrane helix. 
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Human BCRP encodes a 655 amino acid ABC protein, containing a single N-
terminal ATP binding cassette, followed by 6 putative transmembrane segments 
(TMSs). Based on structural and sequence homology, BCRP belongs to the 
ABCG gene family. 
 
There is considerable, but varying overlap in anticancer drug substrate specificity 
between BCRP on the one hand and Pgp, MRP1, and MRP2 on the other hand. 
Cell lines selected for resistance to mitoxantrone, topotecan, doxorubicin, SN-38 
and flavopiridol all overexpressed BCRP, strongly suggesting that these drugs are 
transported substrates for BCRP (Dahan, Amidon 2009), (Mahringer, Delzer & 
Fricker 2009). 
 
 
 
 
 
 
 
Figure 13: Structure of Mitoxantrone; a BCRP substrate. 
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Drug-selected BCRP-overexpressing cell lines displayed high cross-resistance to 
daunorubicin, epirubicin, 9-aminocamptothecin, bisantrene, etoposide and 
teniposide (Sargent et al. 2001), (Kamiyama et al. 2006), (Plasschaert et al. 2004), 
(Shiozawa et al. 2004), (Solazzo et al. 2009). In some selected cell lines, BCRP 
conferred resistance to anthracyclines, whereas in other cell lines there was hardly 
any resistance to anthracyclines compared to mitoxantrone resistance, which was 
consistently high. Moreover, topotecan resistance was generally quite high, but 
low in some BCRP-overexpressing lines. Honjo et al. recognized that two BCRP-
overexpressing lines (MCF-7/AdVp3000 and S1-M1-80, each with high 
anthracycline resistance) could efflux rhodamine 123 efficiently, whereas all other 
BCRP-overexpressing lines tested could not (Honjo et al. 2001).  
 
Sequence analysis revealed that the rhodamine-extruding lines contained a mutant 
%&53GHYLDWLQJIURPWKHµZLOG-W\SH¶%&53DWDUJLQLQHZKLFKZDVUHSODFHG
with either threonine (in the MCF-7/AdVp3000 line) or glycine (in the S1-M1-80 
line). The MCF-7/AdVp3000 line had been the source of the first cloned BCRP 
cDNA (Doyle et al. 1998), which therefore represented a mutant BCRP. Further 
experiments confirmed that the wild-type (R482) BCRP could efficiently extrude 
mitoxantrone, but not rhodamine 123 or doxorubicin. In contrast, both R482T and 
R482G mutants efficiently extruded all three compounds. In the parental cell 
lines, only the wild-type BCRP sequence was found, indicating that in some lines 
the extended drug selection must have resulted in selection of mutant BCRPs that 
were more efficient in conferring resistance to the selecting drug. 
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1.2.3.4.1. Inhibitors of Breast cancer resistant protein 
 
GF120918, a highly efficient Pgp inhibitor that can be used in animals and 
patients, is also an effective BCRP inhibitor (Maliepaard et al. 2001b). GF120918 
is not a specific BCRP inhibitor, but for some clinical applications this may be an 
advantage, as two multidrug transporters, BCRP and Pgp, each with their own 
potentially adverse activity, can be blocked at the same time. 
 
 
 
 
 
 
 
 
Figure 14: Structure of fumitremorgin C; a potent BCRP inhibitor 
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In a systematic search for drug resistance-reversing compounds, fumitremorgin C 
(FTC), a tremorgenic mycotoxin produced by the fungus Aspergillus fumigatus, 
was found to effectively reverse drug resistance and increase cellular drug 
accumulation in BCRP-expressing cells (Rabindran et al. 2000). FTC inhibited 
BCRP in vitro at concentrations well below those toxic to cultured cells, and had 
little effect on Pgp- or MRP1-mediated drug resistance. This relative specificity 
makes FTC very useful for cell pharmacological studies of BCRP, but its 
neurotoxic effects limit its application in animals or patients. Van Loevezijn et al. 
tested 42 tetracyclic indolyl diketopiperazine analogues of FTC as inhibitors of 
human BCRP. The most potent analogues (Ko132 and Ko134) have comparable 
or greater activity than FTC (van Loevezijn et al. 2001). The HER tyrosine kinase 
inhibitor, CI1033, also inhibits BCRP, although with moderate affinity. CI1033 
also appears to be a transported substrate for BCRP (Erlichman et al. 2001). 
 
1.2.3.4.2. Tissue distribution of Breast cancer resistant protein 
 
Very high BCRP RNA expression was found in human placenta, but in murine 
placenta the expression of Bcrp1 was quite moderate. In contrast, mice displayed 
highest expression of Bcrp1 RNA in kidney, where humans appear to have low 
BCRP expression (Tanaka et al. 2004). The immunohistochemical studies by 
Maliepaard et al. used two independent monoclonal antibodies, BXP-21 and 
BXP-34, recognizing human BCRP (Maliepaard et al. 2001b). BCRP was 
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detected in the placental syncytiotrophoblast plasma membrane facing the 
maternal bloodstream, in the bile canalicular membrane of the liver hepatocytes 
and in the luminal membrane of villous epithelial cells in the small and large 
intestine, locations shared with Pgp. BCRP was further found in the apical side of 
part of the ducts and lobules in the breast, and in the venous and capillary 
endothelial cells of practically all tissues analysed, but not in arterial endothelium 
(Maliepaard et al. 2001a). A recent study by Scharenberg et al. demonstrated a 
very similar distribution of BCRP expression in the human hematopoietic 
compartment, with high expression in putative hematopoietic stem cells, and 
much decreased expression in committed progenitor cells, which only comes up 
again in natural killer cells and erythroblasts, but not in other differentiated 
lineages (Scharenberg, Harkey & Torok-Storb 2002). 
 
1.3 Cellular membrane affinity chromatography  
 
It is clear from the above discussion that the ABC transporters play a very 
important role in clinical MDR in human GBM and also have a profound effect 
on reducing the oral bioavailability of substrate drugs. Also there are limited if 
any, tools available for screening lead candidates for possible transport by the 
ABC transporters. Cellular membrane affinity chromatography (CMAC) can be 
used to immobilize membrane fragments expressing target proteins. These 
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columns can be used to study binding parameters of ligands with target proteins 
and also to screen chemical libraries for drug discovery. 
The approach utilized in this work is based upon affinity chromatography. The 
PHFKDQLVP RI DIILQLW\ VHSDUDWLRQV LVPRVW RIWHQ GHVFULEHG E\ D ³ORFN DQG NH\´
analogy. Retention depends on complementarity of a ligand PROHFXOHWKH³NH\´
DQGDVSHFLILFELQGLQJVLWHWKH³ORFN´ZLWKKLJKDIILQLW\IRUWKHOLJDQG7\SLFDOO\
the molecule containing the binding site is a protein, although some nucleic acid 
interactions may also be useful. The ligand can be a small molecule, a 
carbohydrate, another protein, a prosthetic group, a specific amino acid sequence 
in a protein, or a specific nucleotide sequence. There are virtually an unlimited 
number of affinity separations that can be used, the only requirement being a 
strong and specific binding interaction that is in some way reversible. 
 
In some cases the ligand is covalently bound to the stationary media. The affinity 
adsorbent thus constructed can be used to specifically scavenge proteins or other 
macromolecules containing a binding site from a sample which may be a complex 
mixture containing many other non-binding molecules. This strategy has been 
used to isolate proteins with binding sites for specific cofactors, enzyme 
inhibitors, cell-surface carbohydrates, and nucleic acid sequences, among other 
possibilities. 
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In other cases a protein with affinity for a specific ligand or sequence is 
covalently bound to the media and used to scavenge the ligand, or a molecule to 
which the ligand is covalently attached, from solution. This approach has much in 
common with the fundamental processes of drug action, absorption, distribution, 
excretion and receptor activation which are dynamic in nature and have 
similarities with the basic mechanisms involved in chromatographic distribution. 
Indeed, the same basic intermolecular interactions (hydrophobic, electrostatic, 
hydrogen bonding) determine the behaviour of chemical compounds in both 
biological and chromatographic environments.  
 
The relationships between pharmacological and chromatographic processes have 
been emphasized by the inclusion of a wide variety of proteins as active 
components of chromatographic systems, in the creation of protein-based 
stationary phases. The extreme complexity of biological systems limits rational 
design of an individual chromatographic system that would directly mimic a total 
biological system. However, construction of the right protein-based stationary 
phase can readily yield a great amount of diversified, precise and reproducible 
data about key aspects of that system. The possibilities are only limited by the 
ability to create and use unique phases. In addition, the ability of enzymes and 
carrier proteins to act as chiral selectands has been extensively used in drug 
development, as well as adapted for use in the chromatographic sciences.  
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An example of the utility of the latter approach is the creation of chiral stationary 
phases (CSPs) through the immobilization of biopolymers on chromatographic 
backbones. These CSPs have been based upon enzymes and carrier proteins and 
used primarily in liquid chromatographic systems. The use of biopolymeric based 
CSPs has been particularly valuable in the quantification and separation of small 
chiral compounds on an analytical scale. 
 
  
 
 
 
 
 
 
 
Figure 15. The chemical structure of the monolayer that is covalently bound to 
the silica on the IAM-PC particles (12 micron, 300  pores). 
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In general, two approaches have been used in the construction of biopolymer-
based CSPs ± covalent immobilization and entrapment/adsorption. The enzymes 
Į- chymotrypsin (ACHT), trypsin (TRYP) and cellobiohydrolase I have been 
covalently attached to silica, ACHT and TRYP have been entrapped in the 
interstitial spaces of an immobilized artificial membrane stationary phase (IAM), 
while ACHT has been adsorbed on LiChrospher phases. The carrier protein 
phases have been synthesized using entrapment followed by cross-linking as in 
WKHFDVHRIĮDFLGJO\FRSURWHLQ$*3RUWKURXJKFRYDOHQWLPPRELOL]DWLRQXVHG
when immobilizing serum albumin. 
 
Biopoylmeric baVHG&63¶VKDYHDOVRIRXQGDXVHLQSKDUPDFRORJLFDODSSOLFDWLRQV
The immobilization of proteins has also been widely studied and a variety of 
covalent and non-covalent immobilization techniques have been developed. In 
addition, the experimental approaches to the isolation and purification of 
receptors from biological matrices have been extensively studied and discussed.  
It has been demonstrated in recent work that these techniques can be used to 
immobilize transporter proteins such as the P-glycoprotein transporter (Pgp), 
carrier proteins such as human serum albumin (HSA) and receptor proteins such 
as nicotinic acetylcholine receptors. The nicotinic receptor and Pgp were 
immobilized via hydrophobic insertion into the interstitial spaces of an 
immobilized artificial membrane (IAM) stationary phase (Figure 15). The IAM is 
FRPSULVHGRIVLOLFDSDUWLFOHVȝPLGZLWKcSRUHVWRZKLFKSKRVSKROLSLG
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analogues, with functional head groups, have been covalently coupled in a 
monolayer. 
 
1.3.1. Principles of cellular membrane affinity chromatography 
 
CMAC utilizes affinity chromatography as its principle. The mechanism of 
affinity separations is a complimentary relationship between a ligand and its 
substrate. The molecule containing the binding site is a protein. The ligand is a 
small molecule. There are various affinity separations that can be used; the only 
requirement is that the binding should be specific and reversible. The receptor of 
interest is immobilized via hydrophobic insertion into the interstitial spaces of an 
immobilized artificial membrane (IAM) stationary phase. The IAM is comprised 
RIVLOLFDSDUWLFOHVȝPLGZLWKcSRUHVWRZKLFKSKRVSKROLSLGDQDORJXHV
with functional head groups, have been covalently coupled in a monolayer. The 
specific feature of IAM beads is its resemblance to a hydrophobic environment 
that allows immobilization of membrane proteins and receptors.   
 
The stationary phases can be characterized using frontal chromatographic 
experiments. Binding affinities (expressed as dissociation constants, Kd) are 
determined using the stationary phases and in some cases a mixtures of ligands 
are resolved according to their relative affinities. 
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In frontal affinity chromatography a larger sample volume is required than zonal 
elution. A marker ligand is placed in the mobile phase and passed through the 
column. The frontal regions are composed of the relatively flat initial portion of 
the chromatographic traces, which represent the nonspecific and specific binding 
of the marker to the cellular membranes and the target (Figure 16). The saturation 
of the target by the marker produces a steep rise in the chromatographic trace, 
which ends, or plateaus, when the target is saturated. 
Figure 16. Schematic of a frontal chromatogram showing a saturation binding 
curve of the marker ligand when placed in the mobile phase and passed 
through the chromatographic column. The plot looks like the familiar 
sigmoidal dose-response curve or is described as a rectangular hyperbola or a 
binding isotherm curve.  
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Frontal affinity chromatography can be used to calculate the dissociation constant 
Kd and the number of active binding sites Bmax. 
 
The Kd value is used to describe how tightly a ligand (such as a drug) binds to a 
protein. Such binding is usually non-covalent, i.e., no chemical bonds are made or 
broken. Since the binding is usually described by a two-state process 
 
  
the corresponding dissociation constant is defined 
 
where [P], [L] and [C] represent the concentrations of the protein, ligand and 
bound complex, respectively. The Kd has the units of concentration (M), and 
corresponds to the concentration of ligand [L] at which the binding site on the 
protein is half occupied, i.e., when the concentration of protein with ligand bound 
[C] equals the concentration of protein with no ligand bound [P]. The smaller the 
dissociation constant, the more tightly bound the ligand is; for example, a ligand 
with a nanomolar (nM) dissociation constant binds more tightly than a ligand with 
a micromolar ȝ0GLVVRFLDWLRQFRQVWDQW 
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Kd and Bmax values can be obtained from frontal chromatographic data using 
one of two models, a) linear regression model or b) non-linear regression model. 
(Gottschalk et al., 2002) 
For the linear regression model, the association constants of the competitive 
ligands (CL), KCL, as well as the number of the active and available binding sites 
of immobilized receptors, Bmax, were calculated using the following equations 
[(1) and    (2)] 
 
(VmaxíV)í=(1+[M]KM)(Vmin[Bmax]KM)í+(1+[M]KM)2(Vmin[Bmax]KMKCL)í[drug]í  
(1) 
 
(VíVmin)í=(Vmin[Bmax]KCL)í+(Vmin[Bmax])í[M]        
(2) 
   
where, V is the retention volume of the marker ligand (M); Vmax the retention 
volume of M at the lowest concentration and in the absence of drugs; Vmin the 
retention volume of M when the specific interaction is completely suppressed. 
The value of Vmin is determined by running M in a series of concentration of drugs 
and plotting 1/(VmaxíV) versus 1/[CL] extrapolating to infinite [CL]. From the 
above plot and a plot of 1/(VíVmin) versus [M], dissociation constant values, Kd, 
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for M and CL can be obtained as can the number of active binding sites on the 
immobilized protein [Bmax].  
 
In the non-linear regression model the relationship between displacer 
concentration and retention volume can be established using Equation 3 and can 
be used to determine the Kd value of the displacer and the number of active 
binding sites, Bmax.   
 
                 [X] (V - Vmin) = Bmax [X] (Kdx + [X])-
1                (3)          
                        
where: V is retention volume of drug (displacer); Vmin, the retention volume of 
drug (displacer) when the specific interaction is completely suppressed (this value 
can be determined by running the drug with a high concentration of displacer).  
 
An example of a non-linear regression model is shown in Figure 17, where [X] (V 
- Vmin) is plotted vs [X]. The plateau represents the Bmax where all the sites are 
saturated and 50% of the Bmax represents the Kd. 
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Figure 17. A representative non-linear regression plot of [concentration] M vs. 
[conc](V-Vmin)  that results from the data obtained from frontal 
chromatography which is used to derive the dissociation constant Kd and the 
number of active binding sites Bmax. 
 
In affinity chromatography various isotherm equations may arise according to the 
chemical system considered. For the interaction of the solute and the immobilized 
ligand, non-equilibrium conditions must be taken into account. The association 
constants measured between the solute and the immobilized ligand are hardly 
comparable to the solvated conditions. Thus the trend is then to produce 
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immobilized ligands with affinity properties as close as possible to those of the 
free ones, to decrease the nonspecific interactions of the support itself. Frontal 
affinity chromatography decreases the nonspecific interactions between the solute 
and the immobilized ligand as it saturates the column. Thus for measuring the 
equilibrium constants of complicated systems frontal elution is a powerful tool, 
since the amount of interacting biopolymers/compounds at equilibrium is easily 
related to the chromatographic data.   
 
1.4. Aims and objectives 
 
ABC transporters like Pgp, MRP1, MRP2 and BCRP are capable of transporting a 
wide range of compounds. The transported ligands include commonly used anti-
cancer agents, anti-malarial drugs, and anti-HIV drugs like the protease inhibitors. 
Active efflux of the aforementioned substrates leads to insufficient intracellular 
concentration, thereby leading to decreased or no therapeutic effect. Innate and 
over-expression of these ABC transporters in cancer patients leads to clinical 
MDR.  
 
GBM is the third most common cause of death by cancer in the world. GBM 
patients almost always develop resistance to commonly used chemotherapy 
regimen. Hence the initial aim of this research programme was to understand the 
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expression profile of ABC transporters in human GBM cell lines. Biological and 
cellular techniques like immuno-blotting and confocal laser microscopy were to 
be used to assess the expression and localization profiles of the ABC transporters 
in GBM in vitro models. It was proposed to investigate functional activity by 
using efflux and cell proliferation assays and to use immuno-histochemistry to 
study the clinical significance of the ABC proteins in healthy and GBM autopsy 
specimens. 
 
One of the most widely accepted approaches to circumvent clinical MDR has 
been to co-administer specific ABC inhibitors with anti-cancer agents, thereby 
ensuring sufficient intracellular concentrations. The challenge however had been 
to identify specific inhibitors.  
 
The secondary aim of the programme was to develop stationary phases with 
immobilized ABC receptors. These stationary phases would be characterized by 
frontal displacement chromatography and used to study binding interactions of 
known ligands to the ABC proteins. It was envisioned that these columns would 
be an important aid in discovering potential ABC protein inhibitors. 
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Chapter 2 
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2. Identification of ABC transporters in human astrocytomas and 
glioblastoma multiforme cell lines 
 
2.1. Introduction 
 
As discussed in Chapter 1, malignant astrocytomas and glioblastomas are often 
refractory to chemotherapy. Several factors like poor drug penetration contribute 
to the MDR phenotype. A particular problem is active expression of the ABC 
efflux transporters at the blood brain barrier and this poses a formidable challenge 
for effective chemotherapy. In addition to their presence at the BBB, ABC 
transporters have also been reported to be present in tumor cells. However their 
expression profile in human astrocytomas and glioblastoma is contradictory. 
While significant Pgp expression was reported in glioblastoma cell lines 
(Calatozzolo et al. 2005), no Pgp presence was reported by Matsumoto et al 
(Matsumoto et al. 1991). Similar results have been reported for MRP2 
(Matsumoto, Tamiya & Nagao 2005) and BCRP (Carcaboso et al. 2010).  
 
The poor prognosis of glioma patients is partly based on the minor success 
obtained from chemotherapeutic treatments. Resistance mechanisms at the tumor 
cell level may be, in addition to the blood±brain barrier, involved in the intrinsic 
chemo-insensitivity of brain tumors. Considerable expression of P-gp was 
101 
 
relatively rare in glioma cells, in contrast to MRP1, which was constitutively 
overexpressed in cells derived from astrocytomas as well as glioblastomas. Also, 
normal astrocytes cultured in vitro expressed high amounts of MRP1 but no 
detectable P-gp. Given the widespread distribution of ABC transporters and role 
in multidrug resistance, it was important to establish the absence or presence of 
the ABC transporters in the astrocytoma and glioblastoma cell lines selected in 
this study. 
 
2.2. Aims and Objectives 
 
The key main therefore at the outset of the research programme was to establish 
the expression profile of Pgp, MRP1, MRP2 and BCRP in human astrocytoma 
and glioblastoma cell lines. The plan was to carry this out by using Western 
blotting. 
 
2.3. Materials and Methods 
2.3.1. Chemicals 
All chemicals were obtained from Sigma Aldrich (St-Louis, MO, USA) unless 
stated otherwise. 
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2.3.2. Cell culture and optimization of cell growth conditions 
 
Glioblastoma and astrocytoma cell lines in the NIH cell bank were chosen for this 
experiment. Cell lines LN229, T98, A172, 1321N1, U87, U118, and U138 cells 
were purchased from American Type Culture Collection (Manassas, VA, USA). 
Cryogenically frozen cells were removed from the -80oC freezer and kept for 
thawing in a water bath controlled at 37oC.  Initially all cell lines were grown in 
'XOEHFFR¶VPRGLILHG(DJOH¶VPHGLXP'-MEM). LN229, T98, A172 and 1321N1 
cell lines responded well to the selected medium hence they were cultured in 
'XOEHFFR¶VPRGLILHG(DJOH¶VPHGLXP'-MEM). The U87, U118 and U138 cell 
OLQHVZHUHFXOWXUHGLQ(DJOH¶VPLQLPXPHVVHQWLDOPHGLXP(-MEM) as prescribed 
by ATCC, with 4.5 g glucose /L (Quality Biological Inc., Gaithersburg, MD, 
USA). This was determined to be the optimum amount of glucose required for 
healthy cell growth. In order to prevent bacterial contamination, both mediums 
were supplemented with penicillin (25 U / ml), streptomycin (25 µg / ml), pyruvic 
acid and 5% v/v feotal calf serum (Thermo Scientific, Waltham, MA, USA) was 
added to the medium as growth supplement. 5% v/v was found to be the optimum 
concentration as cells became contaminated at 10 % v/v serum. Cells were 
maintained at 37 oC in a humidified incubator with 5% CO2. 
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2.3.3. Preparation of whole cell lysates and optimization 
 
In order to ensure significant and accurate protein expression in immunoblotting 
analyses, it is important for the cells to be lysed at their healthiest form. Fully 
confluent cells grown in T175 flasks were lysed in the beginning. Cell 
morphology analysis of the cells under an electron microscope suggested that the 
cells were not in their optimum health. This was further corroborated by the 
Trypan blue dye cell exclusion methods. It was determined that cells at 70% 
confluence would be the most suitable as they were in their linear growth phase. 
Cells at approximately 70 ± 80% confluence were lysed on ice for 20 min in Tris-
HCl [10 mM, pH 7.4] containing 0.15 M NaCl, 5mM EDTA, 1% v/v Triton X-
100, 1:500 dilution of a stock solution of protease inhibitor cocktail, 0.1M sodium 
ortho-vanadate and 0.1 M DTT. 20 minutes of lysis time was determined as the 
upper limit as more lysis time resulted in sub-optimal protein expression. Protease 
inhibitors were added to prevent proteases from denaturing the target protein. 
Triton X-100 was selected as the detergent of choice as the expression of protein 
was found to be significantly expressed. Insoluble material was removed by 
centrifugation (17,000 ! g for 20 min at 4oC) and the supernatant was collected 
and stored at -80 oC until further analysis. 
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2.3.4. Western Blot analysis 
Western blotting is an analytical technique used to detect a specific protein in an 
extract or a lysate. The protein of interest is separated by gel electrophoresis by 
the length of the polypeptide. Once separated, the protein is then transferred to a 
nitrocellulose or PVDF (poly-vinyl difluoride) membrane, where they are probed 
by antibodies specific to the target antigen.  
 
Figure 18. iBlot protein transfer. Protein samples are loaded onto the 
appropriate polyacrylamide gel, as current flows from the copper cathode to the 
anode; proteins are transferred from the polyacrylamide gel on to the PVDF 
membrane based on their size. 
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Protein concentration optimization 
In order to determine the appropriate concentration of the protein to be loaded for 
western blotting experiments, an optimization experiment was conducted by 
loading ȕ-actin protein lysate on a 4-12% gradient SDS-polyacrylamide gel. The 
proteins were transferred onto a PVDF membrane using the iBlot system. Upon 
resolution it was observed (Figure 19) higher concentrations of 150, 125 and 100 
µg produced a significantly large band at the expected 42 kDa size but multiple 
bands were also observed. The protein signal was found to be very week at lower 
concentrations of 50-5 µg. Given these findings, 70 µg was chosen as the 
optimum concentration to be loaded for all subsequent western blotting 
experiments. 
Figure 19: Optimization of loading protein concentration. Housekeeping 
protein ȕ-actin was loaded on a 4-12% SDS-polyacrylamide gel in the 
concentrations of 150 µg to 5 µg. Based on the clarity of the resolution of the 
protein, 70 µg protein was chose as the concentration for subsequent 
experiments. 
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Blocking and washing optimization 
Blocking of non-specific binding is an important step in western blotting. 
Sufficient blocking by a non-specific protein is required in order to ensure the 
primary antibody specifically binds to the target epitope. This also provides a 
secondary screen by preventing non-specific binding. It was determined that 3 
cycles of washing the membranes with 1X PBS were required in order to produce 
clear and distinct protein bands as shown in Figure 19. Insufficient washing and 
blocking led to immunoblots with dark background as shown in Figure 20. 
 
 
 
 
 
 
 
 
Figure 20. Optimization of non-VSHFLILF EORFNLQJ DQGZDVKLQJ Jȕ-actin 
cell lysate was loaded on a 4-12% SDS-polyacrylamide gel. The dark 
immunoblot is indicative of in-sufficient blocking. 
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Primary antibody optimization 
In order to get the best protein resolution, it is imperative to use the appropriate 
concentration of primary target epitope antibody. Optimization experiments for all 
antibodies used in this study were done using known positive controls and a range 
of chosen antibody. As shown in Figure 21, higher concentration of the primary 
DQWLERG\UHVXOWHGLQODUJHµUXQQLQJ¶EDQGV 
 
 
 
 
 
 
 
Figure 21: Primary antibody optimization. Triplicate loads of 70 µg cell lysate 
from LCC6-MDR1(+) cell line were loaded onto a 4-12% SDS-polyacrylamide 
gel. The immunoblot was probed with mouse monoclonal anti-Pgp (clone C219) 
at the concentration of 1:1000 dilution resulting in multiple and thick bands. 
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In the study described in this chapter, the protein concentration of the lysates was 
measured with the BCA protein assay kit (Thermo Scientific, Waltham, MA, 
USA) using BSA (bovine serum albumin) as standard. An equal amount of 3X 
Laemlli sample buffer was added, and the samples (70 µg) were separated by 
electrophoresis using precast 4-12% gradient SDS-polyacrylamide gels 
(Invitrogen, Carlsbad, CA, USA) and transferred to polyvinylidene difluoride 
membranes using iBLOT (Invitrogen).  
 
The membranes were blocked with 5% v/v dry non-fat milk in Tris-buffered 
saline with 0.1% v/v Tween-20 and then probed with mouse monoclonal anti-Pgp 
(clone C219, 1:500 dilution; Alexis Biochemicals, Plymouth Meeting, PA, USA), 
rat monoclonal anti-MRP1 (clone MRPr1, 1:500 dilution, Alexis Biochemicals), 
mouse monoclonal anti-MRP2 (clone M2I-4, 1:500 dilution, Alexis 
Biochemicals), mouse monoclonal anti-BCRP (clone BXP-21, 1:500 dilution; 
Alexis Biochemicals) and mouse monoclonal anti-ȕ-actin (clone AC-15, 1:5000 
dilution; Abcam, Cambridge, MA, USA). This was followed by appropriate 
horseradish peroxidase-conjugated secondary antibodies; ECL Anti-mouse IgG 
(1:5000 dilution; GE Healthcare, Piscataway, NJ, USA) in the case of Pgp, 
053%&53DQGȕ-Actin. MRP1 blots were incubated with ECL Anti-rat IgG 
(1:5000 dilution; GE Healthcare). The ECL Western blotting detection system 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used for visualization. 
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2.4. Results and Discussion 
 
The aim of this study was to establish the expression profile of Pgp, MRP1, 
MRP2 and BCRP in the selected glioma cell lines. While Pgp, MRP1 and MRP2 
have an estimated molecular weight of 170- N'D %&53 DQG ȕ-actin have 
much lower molecular weights; 72 and 42 kDa respectively. Since the size range 
of the target proteins was rather large, a 4-12 % gradient poly-acrylamide gel was 
chosen for the electrophoretic separation. Proven, well-documented and widely 
accepted antibodies were chosen for the immunobloting stage of the study. The 
anti-Pgp C219 clone has been shown to detect a 170 kDa band (Weber, Eckert & 
Mller 2006), (Ambroziak et al. 2010) which corresponds to Pgp. This antibody 
does not cross-react with MRP1 or MRP2. The anti-MRP1, MRPr1 clone detects 
a band of 190 kDa (Calatozzolo et al. 2005), (Rajagopal, Simon 2003). For 
MRP2, the anti-MRP2, M2I-4 clone antibody was used which has been shown to 
detect the MRP2 band of ~200 kDa (Stross et al. 2009). The BXP-21 clone was 
used to detect the BCRP band at 72 kDa as shown by Maliepaard et al. 
(Maliepaard et al. 2001a). 
 
While most cell lines expressed Pgp, MRP1 and MRP2 in varied proportions, 
BCRP was found to be expressed in all the cell lines (Figure 22). Significant 
expression of Pgp was observed in the 1321N1, U118 and U138 cell lines. T98 
and U87 cell lines showed prominent expression of MRP1 and BCRP. MRP2 
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expression was observed in the T98 and the A172 cell lines. The membrane was 
re-SUREHGE\ȕ-actin to ensure equal loading. 
 
 
 
 
 
 
Figure 22. Expression of Pgp, MRP1, MRP2 and BCRP in various 
glioblastoma cell lysates by Western blotting. Proteins extracted from 
glioblastoma cell lines were separated using sodium dodecylsulfate-
polyacrylamide gel electrophoresis and transferred to a PVDF membrane. 
Results shown are from a single experiment and are representative of 3 
different protein extractions. 
 
2.5. Conclusion 
 
The aim of this study was to study the expression profiles of ABC transporters in 
the selected glioma cell lines. Immunoblotting was used as the technique of 
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choice as it provides a specific representation of the target protein. Established 
antibodies were chosen for this study and were optimized for the cell lines by a 
series of primary antibody dilution experiments. Importantly, the selected glioma 
and astrocytoma cell lines were shown to express Pgp, MRP1, MRP2 and BCRP. 
While Pgp was found to be expressed in all the chosen cell lines, 1321N1, U118 
and U138 showed the most expression of Pgp. MRP1 was significantly expressed 
in T98 and U87. While not a lot of MRP2 was found in the glioma cell lines, T98 
and A172 showed some MRP2 expression. Interestingly a uniform expression of 
BCRP was found in all glioma cell lines. Having confirmed the presence of the 
ABC transporters in the glioma cell lines, it was then important to ascertain the 
functionality of the efflux transporters. Vinblastin and mitoxantrone efflux assays 
were developed to assess the functional profile of Pgp, MRP1, MRP2 and BCRP 
using known inhibitors as vinblastine is a known substrate for Pgp, MRP1 and 
MRP2 and mitoxantrone is a well-established substrate for BCRP. 
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Chapter 3 
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3. Efflux Assay To Investigate The Functionality of the ABC 
Transporters Identified in the Glioma Cell Lines. 
 
3.1 Introduction 
 
Having confirmed the presence of Pgp, MRP1, MRP2 and BCRP in the selected 
glioma and astrocytoma cell lines, it was important to determine if the 
aforementioned transporters were functional. To study the functionality of the 
efflux transporters, the innate efflux property of the transporters was used. Efflux 
transporter-expressing cells actively pump substrates out of the cell, which results 
in a lower rate of substrate accumulation, lower intracellular concentration at 
steady state, or a faster rate of substrate elimination from cells loaded with the 
substrate. Transported radioactive substrates or labeled fluorescent dyes can be 
directly measured, or in an indirect set up, the modulation of the accumulation of 
a probe substrate can be determined in the presence of a test drug or an inhibitor. 
Radio labeled vinblastin was chosen as the substrate for this study, as it is widely 
transported by Pgp, MRP1 and MRP2. Mitoxantrone was used as a substrate for 
BCRP. Known inhibitors of ABC transporters like benzbromarone, MK571 and 
sulfinpyrazone were used to study the differential efflux of vinblastin. 
Fumitremorgin-C was used as a BCRP inhibitor. Activity of the multidrug 
transporters was reflected by the difference between the amounts of substrate 
accumulated in the presence and the absence of inhibitor.  
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3.2 Aims and objectives 
 
The aim of this study was to investigate the efflux mechanism of Pgp, MRP1, 
MRP2 and BCRP in the presence and absence of known inhibitors, using a whole 
cell based efflux assay. 
 
3.2 Materials and Methods 
 
25!105 cells/well were seeded in 12 well plates, pre-coated with poly-L-lysine 
(0.0001% solution v/v in 1XPBS; Sigma Aldrich). The plates were coated with 
poly-L-lysine to ensure cell adherence. The 0.0001% v/v concentration did not 
have any effect of healthy cell growth. Cells were allowed to adhere and grow for 
24 h. Cells were washed twice with 1XPBS and pre-treated with specific 
inhibitors or vehicle (DMSO; Sigma Aldrich) for 1h. The inhibitors used for this 
study were benzbromarone, MK571, sulfinpyrazone, indomethacine and FTC. 
The concentrations that were used: 0.5 µM, 5 µM, 10 µM, 50 µM, 100 µM, 250 
µM and 500 µM. 20 nM [3H]-vinblastine sulphate (Amersham; specific activity 
5.90 Ci / mmol) and 20 nM [3H]-mitoxantrone (Amersham; specific activity 4.20 
Ci/mmol) was added to the wells and the cells were incubated for 30 min. The 
extra-cellular medium was collected. Counts were calculated in liquid scintillation 
counter (LSC) vials with 3 ml LSC fluid; Ecoscint A (National Diagnostics). The 
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wells were washed once with 500 µL 1XPBS and lysed by adding 500 µL 1 mM 
NaOH in 1XPBS for 30 min and the intra-cellular medium was collected. 
Radioactivity in both the extra and intra-cellular media was counted by a liquid 
scintillation counter (Beckman LC61000) in LSC vials with 3ml LSC fluid; 
Ecoscint A (National Diagnostics). 
 
3.3 Results and Discussion 
 
Findings from Chapter 2 indicated significant expression of ABC transporters in 
selected GBM and astrocytoma cell lines. Pgp and BCRP expression was uniform 
across all the cell lines, while MRP1 was significantly expressed in T98 and the 
U87 cell lines. MRP2 was found to be expressed in T98 and A172 cell lines. 
Before investigating the localization of the transporters it was thought to be 
important to understand the functionality of the transporters. A radio-labelled 
whole cell based efflux assay was developed to study the export of known 
substrates in absence and presence of known inhibitors. [3H]-vinblastine sulphate 
was used as a substrate for Pgp, MRP1 and MRP2 as it is a known substrate for 
Pgp (Chanmahasathien et al. 2011), (Laska et al. 2002), MRP1 (Saito et al. 2001), 
MRP2 (Evers et al. 2000). For BCRP, [3H]-mitoxantrone was used as it has been 
previously validated as a substrate for BCRP (Takara et al. 2012). 20 nM of both 
[3H]-vinblastine-sulphate and [3H]-mitoxantrone was used for the experiments.  
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Inhibitor Benzbromarone MK571 
 
Indomethacin 
 
Sulfinpyrazone 
 
Fumitremorgin-C 
 
Cell Line 
1321N1 28.81 + 0.05 µM -  - 16  + 0.90 µM 
A172 7.27 + 1.56 µM 6 + 0.68 µM 86 + 1.59 µM 4.53 + 1.59 µM 22 + 0.10 µM 
LN229 13.60 + 0.72 µM 19 + 0.80 µM - - 7  + 0.02 µM 
T98 19.80 + 0.01 µM 11.70 + 1.2 µM 782 + 1.21 µM 8.98 + 0.71 µM 28 + 0.46 µM 
U118 42.71 + 0.09 µM - - 979 + 0.66 µM 72 + 0.38 µM 
U138 11.27 + 0.87 µM - - - 48 + 0.97 µM 
U87 56.03 + 1.31 µM 4.8 + 22 µM - 553 + 1.73 µM 76 + 1.22 µM 
 
Table 1. IC50 values of ABC transporter modulators determined by [
3H]-
vinblastine efflux assay and [3H]-mitoxantrone efflux assay.  n=3. (-) indicates 
no efflux activity was observed. 
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As seen in Table 1, IC50 values indicated significant inhibition of efflux by the 
inhibitors. This data indicates that the ABC transporters present in the GBM and 
astrocytoma cell lines are functional. 
 
3.4 Conclusions 
 
This study confirmed that the ABC transporters in the GBM and astrocytoma cell 
lines were indeed functional. Significant difference was observed in efflux of 
know substrates in absence and presence of known ABC transporter inhibitors. 
Having confirmed the presence and functionality of the ABC transporters, the 
next step was to investigate the localization of the transporters. 
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Chapter 4 
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4. Study of localization of ABC transporters by confocal 
immunofluorescence 
 
4.1. Introduction 
 
Results from the Western blot analysis indicated a significant presence of Pgp, 
MRP1, MRP2 and BCRP in the selected GBM cell lines. The functional efflux 
assay showed that the ABC proteins were indeed active and played a crucial role 
in the MDR phenotype exhibited by the GBM cell lines. The next step towards 
characterizing the ABC proteins in the GBM cell lines was to study their 
localization profile. Confocal laser microscopy was used to investigate the 
location of Pgp, MRP1, MRP2 and BCRP in selected GBM cell lines. 
 
4.2. Aims and Objectives 
 
The aim of the next step in the research programme therefore was to study the 
localization of Pgp, MRP1, MRP2 and BCRP in selected glioma cell lines by 
using confocal laser microscopy. 
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4.3. Materials and Methods 
 
Selected glioma cell lines were harvested at 90% confluency and cell number was 
determined by a trypan blue exclusion method. 25,000 cells were plated on a 
LabTek 4 chamber slide with cover CC2 sterile glass slide (Nalge Nunc 
International # 154917). Following 24 h incubation at 37oC, 5% CO2, the medium 
was replaced with sera free medium and the cells were incubated for a further 2 h 
to equilibrate the protein signal and eliminate any stimulatory or inhibitory effects 
of sera. The cells were washed with 2XPBS and treated with 4% v/v 
formaldehyde at room temperature for 10 min to fix the cells. After 2 washes with 
2 X PBS, the cells were permeablised with 0.2% v/v Triton X-100 for 5 min to 
expose the target epitope. The cells were then treated with 8% v/v BSA (bovine 
serum albumin) at room temperature for 1 h, to block any non-specific binding to 
the primary antibody. The primary monoclonal antibody dilutions, 1:50 [Pgp 
mouse(C219), MRP1 rat(MRPr1), MRP2 mouse(M2I-4) and BCRP 
mouse(BXP21)], were made in 1% v/v BSA and the cells were probed at 4oC, for 
12 h. The cells were washed to remove any unbound antibodies and probed with 
the appropriate secondary antibody. Goat anti-mouse conjugated to Alexa Fluor 
488 in case of Pgp, MRP2 and BCRP and goat anti-rat conjugated to Alexa Fluor 
568 in case of MRP1. At the end of the incubation period the cells were washed 
twice with 2XPBS and mounted with Prolong Gold stain with DAPI for nuclear 
staining. The slides were then analysed by a Zeiss Meta 510 confocal microscope. 
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4.4. Results and Discussion 
 
Confocal microscopy is an optical imaging technique often used in cellular 
studies to investigate the localization of target proteins. A derivative of traditional 
fluorescence microscopy; confocal microscopy has a clear advantage, as the 
microscope uses point illumination as compared to flooding the entire specimen, 
thus decreasing the signal to noise ratio to almost negligible amounts (Shotton 
1989). 
 
Indirect staining was used in the present study as this adds another screen to 
eliminate non-specific binding of either the primary or secondary antibody, as 
only the antigen-antibody complex is illuminated by the fluorophore conjugated 
secondary antibody. Care was taken to eliminate non-specific signals at every step 
with adequate washes with 2 X PBS between every staining step. 4 well chamber 
slides were chosen and the last well of each slide was not probed by the primary 
antibody to provide the negative control for imaging. 
 
Of all the glioma cells lines that were characterized by Western blotting, five were 
chosen based on the expression profile of the ABC transporters. Comparing the 
signal intensity of the Pgp, MRP1, MRP2 and BCRP blots with that of the 
LQWHUQDOVWDQGDUGȕ-actin, it was inferred that Pgp levels were uniform all across 
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the cell lines, MRP1 and MRP2 were abundant in U87, LN229, T98, 1321N1, 
A172 and BCRP was expressed in high amounts in the T98 and LN229 cell lines.  
 
Results from confocal immuno-fluorescence confirmed previous findings from 
immuno-blotting. Pgp was found to be present in 1321N1 (Figure 23), A172 
(Figure 24) and U87 (Figure 25) cell lines, localized on the membrane and in the 
cytosol. MRP1 and MRP2 were present in LN229, T98, U87, 1321N1 and A172. 
As shown in Figure 26, there was co-localization of MRP1 and MRP2 in LN229 
cells, further confirming the specificity of the method and indicating towards the 
over-lap in the localization of the ABC transporters. 
 
BCRP was found to be present in the LN229 and T98 cells as expected. The 
positive signal was observed in the cytoplasm but primarily in the nucleus (Figure 
27 and 28). Although by definition and indeed according to published work the 
ABC transporters are essentially membrane efflux transporters, localized 
primarily on the surface of the cells and in the plasma membrane whereby the 
most efficiently facilitate the extrusion of their substrates (Ambudkar et al. 1999). 
However, there have been isolated reports about BCRP being found in the nucleus 
of chorion leave cells (Yeboah et al. 2008) and in the mitochondria in some 
instances (Solazzo et al. 2009). The exact physiological role that BCRP might 
play in the nucleus is unclear, although it could act as a reservoir for Pkt 
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translocation of the protein or like in the case of hematopoetic stem cells, act like 
a side population of ABCG2 (Zhou et al. 2001). 
 
The primary aim of confocal immunofluorescence was to confirm the absence or 
presence of Pgp, MRP1, MRP2 and BCRP in the selected glioma cell lines. While 
most of the findings were consistent with previously reported immuno-blotting 
data, the localization of BCRP in the nucleus of the T98 and LN229 cells may 
indicate a secondary site for efflux. 
 
 
 
 
 
 
 
Figure 23. Confocal immuno-fluorescence staining of 1321N1 cells using Pgp 
mouse(C219) antibody. Stained with ALEXA Fluor 488 conjugated anti mouse. 
(I) Nuclear staining with DAPI, (II) Pgp staining, (III) Cell morphology 
control, (IV) Merge. Image magnification = 500X 
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Figure 24. Confocal immuno-fluorescence staining of A172 cells using Pgp 
mouse(C219) antibody. Stained with ALEXA Fluor 488 conjugated anti mouse. 
(I) Nuclear staining with DAPI, (II) Pgp staining, (III) Cell morphology 
control, (IV) Merge. Image magnification = 10X 
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Figure 25. Confocal immuno-fluorescence staining of U87 cells using Pgp 
mouse (C219) antibody. Stained with ALEXA Fluor 488 conjugated anti mouse. 
(I) Nuclear staining with DAPI, (II) Pgp staining, (III) Cell morphology 
control, (IV) Merge. Image magnification = 500X 
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Figure 26. Co-localisation of MRP1 and MRP2 in LN229, glioma cells. (I) 
LN229 cells stained with nuclear stain DAPI, (II) LN229 cells stained with 
MRP2 mouse(M2-III4), (III) LN229 cells stained with MRP1 rat(MRPr1), (V) 
Morphology control, indicating the healthy and intact morphology of the 
LN229 cells and (IV) co-localization of MRP1 and MRP2. Image magnification 
= 10X 
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Figure 27. Confocal immuno-fluorescence staining of LN229 cells using BCRP 
mouse(BXP-21) antibody. Stained with ALEXA Fluor 488 conjugated anti 
mouse. (I) Nuclear staining with DAPI, (II) Pgp staining, (III) Cell morphology 
control, (IV) Merge. Image magnification = 10X 
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Figure 28. Confocal immuno-fluorescence staining of T98 cells using BCRP 
mouse (BXP-21) antibody. Stained with ALEXA Fluor 488 conjugated anti 
mouse. (I) Nuclear staining with DAPI, (II) BCRP staining, (III) Cell 
morphology control, (IV) Merge. Image magnification = 10X 
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4.5. Conclusion 
 
Findings from confocal microscopy confirmed data from western blotting in 
Chapter 2. Interestingly, in addition to cytoplasmic expression of Pgp, MRP1, 
MRP2 and BCRP, significant expression of BCRP was observed in the nucleus of 
the LN229 and T98 cells. In order to further investigate this finding, LN229 cells 
were chosen for subcellular fractionation BCRP investigation using immuno-
blotting and confocal microscopy with specific nuclear markers. 
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Chapter 5 
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5. Analysis of nuclear expression of breast cancer resistant protein 
 
5.1 Introduction 
 
At this point in the research programme, the presence of BCRP in the selected 
glioma cell lines had been confirmed by whole cell Western blot analysis and 
confocal microscopy had been used to indicate a significant BCRP localization at 
the nucleus of the LN229 cells. Given the unusual nature of this finding, it was 
thought that it would be useful to confirm it by using sub-cellular fractionation 
Western blotting.  
 
5.2 Aims and Objectives 
 
Accordingly, the aim of this phase of the research programme was to study the 
expression of BCRP in native and BCRP silenced LN229 cells using sub cellular 
fractionation immuno-bloting and confocal microscopy. 
 
 
 
132 
 
5.3      Materials and Methods  
 
5.3.1. Cell culture 
 
LN229 and MCF-7 cells were purchased from American Type Culture Collection 
0DQDVVDV 9$ 86$ 7KH FHOO OLQHV ZHUH FXOWXUHG LQ 'XOEHFFR¶V PRGLILHG
(DJOH¶V PHGLXP '-0(0 DQG (DJOH¶V PLQLPXP HVVHQWLDO PHGLXP (-MEM) 
respectively, with 4.5 g glucose / L (Quality Biological Inc., Gaithersburg, MD, 
USA), supplemented with penicillin (25 U/ml), streptomycin (25 µg/ml), pyruvic 
acid and 5% v/v foetal calf serum (Thermo Scientific, Waltham, MA, USA).  
Cells were maintained at 37oC in a humidified incubator with 5% CO2. 
 
5.3.2 Preparation of whole cell lysates 
 
Cells at approximately 70 ± 80% confluence were lysed on ice for 20 min in Tris-
HCl [10 mM, pH 7.4] containing 0.15 M NaCl, 5mM EDTA, 1% v/v Triton X-
100, 1:500 dilution of a stock solution of protease inhibitor cocktail, 0.1M sodium 
ortho-vanadate and 0.1M DTT (Sigma Aldrich, St-Louis, MO, USA). Insoluble 
material was removed by centrifugation (17,000!g for 20 min at 4oC) and the 
supernatant was collected and stored at -80oC until further analysis. 
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5.3.3. Subcellular fractionation 
 
Nuclear and cytoplasmic lysates were prepared using the NE-PER Nuclear and 
&\WRSODVPLF ([WUDFWLRQ 5HDJHQWV NLW DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V SURWRFRO
(Thermo Scientific, Waltham, MA, USA). 
 
5.3.4. Western Blot analysis 
 
The protein concentration of the lysates was measured with the BCA protein 
assay kit (Thermo Scientific, Waltham, MA, USA) using BSA as standard. An 
equal amount of 3X Laemlli sample buffer was added, and the samples (70 µg) 
were separated by electrophoresis using precast 4-12% gradient SDS-
polyacrylamide gels (Invitrogen, Carlsbad, CA, USA) and transferred to 
polyvinylidene difluoride membranes using iBLOT (Invitrogen). The membranes 
were blocked with 5% v/v dry non-fat milk in Tris-buffered saline with 0.1% v/v 
Tween-20 and then probed with mouse monoclonal anti-BCRP (clone BXP-21, 
1:500 dilution; Alexis Biochemicals, Plymouth Meeting, PA, USA) and mouse 
monoclonal anti-ȕ-actin (1:5000 dilution; Abcam, Cambridge, MA, USA) as a 
loading control. The quality of the cytoplasmic and nuclear extracts was 
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FRQILUPHG E\ SURELQJ WKH EORWV IRU WKH F\WRSODVPLF PDUNHU 1)ț% S XVLQJ
mouse monoclonal anti-1)ț% S FORQH )-6, 1:5000 dilution; Santa Cruz 
Biotechnology, Inc., Santa Cruz, California, USA) and the nuclear marker Brg-1 
using mouse monoclonal anti-Brg-1 (clone G-7, 1:5000 dilution; Santa Cruz 
Biotechnology). This was followed by appropriate horseradish peroxidase-
conjugated secondary antibodies. The ECL Western blotting detection system 
(Santa Cruz Biotechnology) was used for visualization. 
 
5.3.5. BCRP siRNA transfection 
 
Subconfluent LN229 and MCF-7 cells were transfected with a pool of three 
BCRP siRNA oligonucleotides; s18056, s18057 and s18058 (Ambion, Austin, 
TX, USA) and a siRNA non-targeting control, 4390844 (Ambion), using forward 
WUDQVIHFWLRQ WHFKQLTXHZLWK/LSRIHFWDPLQH51$L0$;,QYLWURJHQ DFFRUGLQJ
WRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV%ULHIO\Q0VL51$ZDVPL[HGZLWK/
/LSRIHFWDPLQH51$L0$;DQGZDV DOORZHG WR IRUP D VL51$-Lipofectamine 
complex for 20 min at room temperature. Cells were harvested, re-suspended in 
appropriate media without penicillin-streptomycin and seeded with the siRNA-
Lipofectamine complex. After 48-72 hr, the cells were assayed for BCRP 
knockdown.  
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5.3.6. Confocal microscopy 
 
LN229 cells (25!103 cells/well) and MCF-7 cells (15!103 cells/well) were seeded 
on a 4-well LabTek II CC2 chamber slide system with lid (Nalge Nunc 
International, Roskilde, Denmark) and allowed to grow for 24 h. The medium was 
replaced with serum-free medium for 2 h, after which the cells were washed twice 
with phosphate-buffered saline (PBS) and fixed with 4% v/v formaldehyde 
(Sigma Aldrich) at room temperature for 10 min. After fixing, the cells were 
washed twice with PBS, permeabilized with 0.2% v/v Triton X-00 (Sigma 
Aldrich) for 5 min, washed again with PBS, and then blocked with 8% v/v BSA at 
room temperature for 1 h. The mouse monoclonal anti-BCRP (clone BXP-21; 
1:500 dilution) and rabbit polyclonal anti-emerin (1:1000; Abcam) were diluted 
with 1% v/v BSA and added to the cells for 12 h at 4oC. After three PBS washes, 
Alexa Fluor 488 conjugated goat anti-mouse and Alexa Fluor 568 conjugated goat 
anti-rabbit antibodies were added to the slides and the cells were incubated at 
room temperature for 1 h. The cells were washed three times with PBS, mounted 
in Prolong Gold antifade (Invitrogen) and cured for 24 h at room temperature in 
the dark. Images were taken using a Zeiss Meta 510 confocal microscope.  
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5.4. Results and Discussion 
 
5.4.1. Subcellular fractionation analysis of breast cancer resistant protein 
 
Nuclear and cytoplasmic fractions from the LN229 and MCF-7 cells were probed 
for BCRP. The LN229 and MCF-7 cells were also probed BCRP and emerin to 
study any nuclear co-localization, since emerin is a nucleus specific lamin protein. 
Expression of BCRP was determined in the LN229 cells by Western blotting 
using a BCRP specific monoclonal antibody; clone BXP-21 (Maliepaard et al. 
2001a). The human derived breast adenocarcinoma cell line, MCF-7, was used as 
positive control as it has been previously demonstrated that BCRP is expressed in 
this cell line (Burger et al. 2004). The results from the whole cell lysates 
demonstrated that BCRP was expressed in both the LN229 and MCF-7 cell lines 
(Figure 29$ 'HQVLWRPHWULF FDOFXODWLRQV XVLQJ ȕ-actin as the loading control 
indicated that there were no significant differences in the relative expression of 
BCRP in the LN229 and MCF-7 cell lines.  
 
Cytoplasmic and nuclear extracts were obtained from the whole cell lysates of the 
LN229 and MCF-7 cells by subcellular fractionation, and the fractions were 
probed for BCRP by Western blot analysis.  The results indicate that BCRP was 
expressed in both the cytoplasmic and nuclear fractions of LN229 cells (Figure 
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29B).  A direct comparison of the intensities of the BCRP bands indicates that the 
nuclear expression of BCRP was ~2-fold greater than in the cytosolic fraction. In 
contrast, BCRP was readily observed in the cytosolic fractions prepared from 
MCF-7 cells, but was not detected in the nuclear extracts of these cells (Figure 
29B).  
 
The expression of BCRP in LN229 and MCF-7 cells was further probed using a 
pool of siRNAs targeted against the BCRP gene.  siRNA-mediated BCRP gene 
knockdown resulted in a significant reduction (~80%) in the relative expression of 
BCRP transcript in LN229 and MCF-7 cell lines when compared to cells 
transfected with a control non-targeting siRNA (Figure 29C). To investigate the 
effect of gene silencing on the subcellular compartmentalization of BCRP, 
cytoplasmic and nuclear extracts were prepared from LN229 and MCF-7 cells 
that were transfected with either control or BCRP siRNAs.  There was significant 
reduction in BCRP levels in the nuclear fraction of LN229 cells treated with 
BCRP siRNAs, while BCRP could no longer be detected in the cytoplasmic 
fraction of these cells (Figure 29D). BCRP was not detected in either the 
cytoplasmic or nuclear fraction of the MCF-7 cells depleted of BCRP (Figure 
29D). 
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Figure 29. Detection of BCRP by immunoblot analysis. (A) The human brain 
tumor cell line LN229 and the MCF-7 breast cancer cells were lysed and 
SURFHVVHG IRU:HVWHUQ EORW DQDO\VLV 7KH EORWVZHUH SUREHG IRU%&53DQG ȕ-
actin expression using specific primary antibodies. The molecular mass 
markers (in kDa) are shown on the right. (B) Cytosolic and nuclear extracts of 
LN229 and MCF-7 cells were resolved by SDS-polyacrylamide gel 
electrophoresis and subjected to Western blot analysis for the detection of 
BCRP. The membranes were reprobed with antibodies against the cytosolic 
marker, p65Rel [a subunit of N)ț%@DQGWKHQXFOHDUPDUNHU%UJ1 to confirm 
the quality of the subcellular fractionation. (C) LN229 and MCF-7 cells were 
transfected with a siRNA non-targeting control or BCRP siRNAs for 24 h, after 
which cells were lysed and processed for the detection oI%&53DQGȕ-actin by 
immunoblot analysis. (D) Cytosolic and nuclear extracts were prepared from 
control and BCRP siRNA-treated LN229 and MCF-7 cells followed by Western 
blot analysis using the indicated antibodies. Similar results were obtained in 
three independent experiments. 
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5.4.2. Confocal microscopy analysis of breast cancer resistant protein co-
localization with emerin  
 
Indirect immunofluorescence confocal laser microscopy was used to further 
investigate the localization profile of BCRP in the LN229 and MCF-7 cell lines 
(Figure 30). Significant cytosolic localization of BCRP was observed in both cell 
lines (Figure 30A, upper panels). Co-staining of emerin indicated significant 
nuclear localization of BCRP in the LN229 cells, but not MCF-7 cell line (Figure 
30A, middle and bottom panels). These results are in agreement with the data 
from the Western blot studies. Vertical sections in the x-z and y-z planes of 
confocal images were generated to confirm BCRP co-localization with emerin 
(Figure 30B). The x-z plane generated from fixed LN229 cells showed staining 
consistent with their co-localization (depicted in yellow). Using the same 
approach, no detectable nuclear expression of BCRP was observed in MCF-7 
cells, as there was a clear demarcation of BCRP and emerin staining with no co-
localization. Cross-sectional quantification of the images indicated the signal 
intensity to be uniform in both sets of images.  
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Figure 30. Cellular distribution of BCRP by confocal laser microscopy. LN229 
cells and MCF-7 cells were transfected with control and BCRP siRNAs for 24 
h. Cells were then fixed and immunolabeled with monoclonal anti-BCRP 
(green, upper panels) and polyclonal anti-emerin (red, middle panels) 
antibodies. Merge images are shown in the bottom panels. Areas of nuclear co-
localization between BCRP and emerin appear in yellow in LN229 cells, which 
were absent in MCF-7 cells. Similar results were obtained in three independent 
experiments. Magnification 40X, (A) XY plane; (B) XZ plane.  
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5.5. Conclusion 
 
The results demonstrated that in the human-derived LN229 GBM cell line BCRP 
is expressed in both the cellular and nuclear membranes, with nuclear expression 
predominating.  The data from the Western blot, confocal laser microscopy and 
siRNA knockdown studies confirm the presence of BCRP in the nucleus. Clearly 
this could have significant functional consequences, which would have to be 
investigated.  
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Chapter 6 
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6. Functional analysis of nuclear breast cancer resistant protein 
 
6.1. Introduction 
 
Subcellular fractionation and siRNA transfection studies had confirmed the 
nuclear presence of BCRP in the LN229 GBM cells and Z-section confocal 
imaging further consolidated the finding, showing significant co-localization of 
BCRP with the nuclear specific marker; emerin. While the exact purpose and 
reason for this was unknown, it was hypothesized that the nuclear location of 
BCRP acts as a secondary efflux site for substrates. In order to investigate this 
line of thought, it was important to assess the functional role of nuclear BCRP in 
the LN229 cells. It was thought that this could be investigated by an MTS cell 
proliferation assay. The non-radioactive MTS [(3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)] cell proliferation 
assay is such an assay, which could be used to study the role of BCRP in the 
LN229 GBM cells. It is a colorimetric technique to assess the viability and 
proliferation of cells in a 96 well system. It relies on the ability of mitochondria in 
live cells to convert the MTS dye into a purple colour formazan, which has an 
absorbance maximum at 490-500 nm. 
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6.2. Aims and Objectives 
 
The aim of this part of the study was to investigate the functional role of nuclear 
BCRP in the effect of mitoxantrone on the LN229 GBM cells. 
 
6.3. Materials and Methods 
 
6.3.1. Cell culture 
 
LN229 cells were purchased from American Type Culture Collection (Manassas, 
9$86$7KHFHOOOLQHVZHUHFXOWXUHGLQ'XOEHFFR¶VPRGLILHG(DJOH¶VPHGLXP
(D-MEM) with 4.5 g glucose / L (Quality Biological Inc., Gaithersburg, MD, 
USA), supplemented with penicillin (25 U/ml), streptomycin (25 µg / ml), 
pyruvic acid and 5% feotal calf serum (Thermo Scientific, Waltham, MA, USA).  
Cells were maintained at 37 oC in a humidified incubator with 5% CO2. 
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6.3.2. BCRP siRNA transfection 
 
Subconfluent LN229 cells were transfected with a pool of three BCRP siRNA 
oligonucleotides; s18056, s18057 and s18058 (Ambion, Austin, TX, USA) and a 
siRNA non-targeting control, 4390844 (Ambion), using forward transfection 
WHFKQLTXH ZLWK /LSRIHFWDPLQH 51$L0$; ,QYLWURJHQ DFFRUGLQJ WR WKH
PDQXIDFWXUHU¶V LQVWUXFWLRQV %ULHIO\  Q0 VL51$ ZDV PL[HG ZLWK  /
/LSRIHFWDPLQH51$L0$;DQGZDV DOORZHG WR IRUP D VL51$-Lipofectamine 
complex for 20 min at room temperature. Cells were harvested, re-suspended in 
appropriate media without penicillin-streptomycin and seeded with the siRNA-
Lipofectamine complex. After 48-72 h, the cells were assayed for BCRP 
knockdown.  
 
6.3.3. MTS assay 
 
The non-radioactive CellTiter 96¨ Aqueous cell proliferation assay was 
SHUIRUPHG DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V SURWRFRO 3URPHJD 0DGLVRQ :,
USA). Briefly, cells were seeded in 96-well plates at a density of 3.5!103 
cells/well and cultured for 24 h. Stock solutions of MTX (Sigma Aldrich) and 
Fumitremorgin C (FTC, Sigma Aldrich) were prepared in DMSO, each at 1 mM. 
FTC is a fungal toxin that has been shown to reverse resistance to doxorubicin, 
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MTX, and topotecan in BCRP-expressing cells at micromolar concentrations. 
MTX was diluted in cell culture medium with a maximum of 0.5% v/v DMSO to 
each well. The concentrations of MTX were 0.5, 5, 50, 500, 1000, 2500 and 5000 
nM. After 48 h incubation, 20 µl of 0.5 mg/ml of the tetrazolium compound MTS 
was added to each well and further incubated for 1 h. The absorbance was 
measured at 490 nm with a micro-plate reader (Thermo Scientific). Change in 
growth rate was calculated as follows: [A490nm of treated cells/A490nm of control 
cells].  
 
6.4. Results and Discussion 
 
The functional activity of BCRP was studied in LN229 cells using MTX, a 
commonly used chemotherapeutic agent that acts as a DNA intercalating agent, 
and FTC, a specific, selective, and potent BCRP inhibitor (Rabindran et al. 2000).  
MTX had been identified as a specific substrate of BCRP efflux activity (Kodaira 
et al. 2010) and previous studies had demonstrated that the cytotoxicity of MTX is 
directly related to intracellular concentration (Jansen, Yip & Louis 2010).  In the 
current study described here, the growth inhibitory activity of 500 nM MTX was 
determined in LN229 cells transfected with either a negative, non-silencing 
control siRNA or BCRP siRNA with and without the addition of 5 ȝ0 )7&
(Figure 31B). The addition of FTC in LN229 cells transfected with control siRNA 
produced a ~20% increase in MTX-mediated growth inhibition (n=3, p < 0.001) 
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as assessed by the MTS assay.  BCRP gene knockdown resulted in a ~50% and 
~70% increase in MTX-dependent growth inhibition, respectively, when MTX 
was added alone (n=3, p < 0.001) or combined with FTC (n=3, p < 0.001). The 
same trend was observed with the calculated MTX IC50 values, which were 
reduced from 570 ± 1.4 nM to 77 ± 0.9 nM by the addition of FTC and to 5.2 ± 
1.1 nM in LN229 cells pre-treated with BCRP siRNA. When the MTS assay was 
repeated using the MCF-7 cell line, the addition of MTX reduced proliferation by 
45% relative to control and co-treatment with FTC increased this effect to 75%.  
The silencing of BCRP in the MCF-7 cells produced no significant differences in 
the cytotoxic potency of MTX when the drug was utilized alone or in combination 
with FTC (Figure 31). This effect was comparable to that of FTC-treated MCF-7 
cells transfected with siRNA negative control. 
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Figure 31. Role of BCRP in LN229 cell proliferation. (A) LN229 cells were 
incubated with the indicated concentrations of mitoxantrone (MTX) in the 
absence (square) or the presence of 5 µM fumitremorgin C (FTC) (diamond) 
for 48 h. A cell proliferation colorimetric assay based on MTS reduction was 
then performed. In some instance, BCRP siRNA-treated LN229 cells were 
incubated with MTX followed by the MTS cell proliferation assay (open 
triangle). (B) LN229 cells were transfected with control or BCRP siRNA for 24 
h followed by the addition of 500 nM MTX in the absence or presence of 5 µM 
FTC for 48 h. Values are means ± SEM from 3 independent experiments 
performed in triplicate. Statistical analysis by ANOVA with 'XQQHWW¶V0XOWLSOH
comparison test was performed, where **P < 0.01 vs. vehicle treated controls 
and *P <0.05 vs. MTX-treated cells transfected with BCRP siRNAs. 
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Figure 32. Comparative study of effect of MTX on BCRP(+) and BCRP(-) 
LN229 and MCF-7 cells. LN229 and MCF-7 cells were transfected with control 
or BCRP siRNA for 24 h followed by the addition of 500 nM MTX in the 
absence or presence of 5 µM FTC for 48 h. Values are means ± SEM from 3 
independent experiments performed in triplicate. Statistical analysis by ANOVA 
ZLWK'XQQHWW¶V0XOWLSOH FRPSDULVRQ WHVW ZDV SHUIRUPHG ZKHUH aP < 0.01 vs. 
vehicle treated controls, bP <0.01 vs. MTX treatment and cP <0.05 vs. MTX-
treated cells transfected with BCRP siRNAs. 
 
 
 
 
150 
 
6.5. Conclusion 
 
The functional consequence of the nuclear expression of BCRP was investigated 
by examining the cytotoxic effect of MTX after competitive inhibition of BCRP 
transport activity by FTC and siRNA reduction of BCRP expression.  In LN229 
cells cytotoxicity was investigated by assessing growth inhibition using the MTS 
assay using the MCF-7 cell line as the positive control as only cytosolic 
expression of BCRP was observed in the MCF-7 cell line.  The data from the 
studies indicated that FTC-mediated inhibition of MTX transport produced a 20% 
increase in growth inhibition, BCRP gene knockdown increased this effect to 
50%, and the combination of the two approaches increased the MTX-dependent 
growth inhibition by 70%.  These results differed from the effects observed with 
the MCF-7 cell line where the co-administration of MTX and FTC decreased 
cellular proliferation by 75%, relative to a 45% reduction observed with MTX 
alone, while the effect of BCRP siRNA was similar to that observed with FTC 
and there was no additive effect produced by combining the two approaches. 
These results indicated that the nuclear expressed BCRP plays a protective role in 
the LN229 cell line and that both a reduction in BCRP expression and its 
competitive inhibition were required to reach the optimum cytotoxic effect of 
either one of these treatments in MCF-7 cells.  
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Chapter 7 
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7. Cellular membrane affinity chromatography 
 
7.1. Introduction 
 
ABC transporters have also been found to be functionally expressed in the human 
GI tract where they limit the bioavailability of their substrates. Most drug 
discovery programmes seek to screen lead candidates for transport by ABC 
proteins like P-glycoprotein (Pgp) using the Caco-2 efflux assay. These cell-based 
assays are time consuming and labour intensive. Also, no definitive assays for 
multidrug resistance protein 1 (MRP1), multidrug resistance protein 2 (MRP2) 
and breast cancer resistant protein (BCRP) had been developed. It was apparent 
that the development of high through-put cellular membrane affinity 
chromatography columns (CMAC), prepared by immobilizing membrane 
fragments from cell lines, stably transfected by Pgp, MRP1, MRP2, BCRP and 
control vectors would enable, screening of potential inhibitors of the ABC 
proteins. 
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7.2. Aims and Objectives 
 
Therefore it was sought to synthesize cellular membrane affinity chromatography 
columns by immobilizing membrane fragments from Sf9 insect cells transfected 
by Pgp, MRP1, MRP2 and BCRP encoding vectors. The stationary phases were 
characterized using displacement frontal affinity chromatography using known 
inhibitors. 
 
7.3.  Materials and methods 
 
7.3.1. Chemicals 
 
[3H]-Etoposide, was obtained from Moravek Biochemicals (Brea, CA, USA). 
MK571 and fumitremorgin C was obtained from Calbiochem (San Diego, CA, 
USA). Etoposide, benzbromarone, (R)-verapamil, (S)-verapamil, furosemide, 
+(3(61D&Oȕ-mercaptoethanol, Tris-HCl, protease inhibitor cocktail (Catalog 
number P8340), adenosine triphosphate (ATP), glycerol, ethylene glycol-bis(2-
aminotheylether)-111¶1¶-tetra-acetic acid (EGTA), glutathione (GSH), 
CHAPS and trizma were purchased from Sigma-Aldrich Co. (St. Louis, MO, 
USA). The immobilized artificial membrane phospahtidyl choline stationary 
154 
 
phase (IAM-PC, 12 µm, 300 ) was purchased from Regis Technologies Inc. 
(Morton Grove, IL, USA).  
 
7.3.2. Sf9 membranes 
 
Sf9-Human MRP1 Membranes (Catalog number 453456), Sf9-Human MRP2 
Membranes (Catalog number 453332) and the Sf9-Human BCRP Membranes 
(Catalog number 453270) isolated from Sf9 cell line transfected with Human 
Mdr1 cDNA, Human Mrp1 cDNA, Human Mrp2 cDNA and Human BCRP 
cDNA genes using a baculovirus system and Control Membranes (Catalog 
number 453200) isolated from non-transfected, native Sf9 cell line were obtained 
from BD Biosciences (Woburn, MA, USA) 
 
7.3.3 Preparation of CMAC(Sf9MRP1), CMAC(Sf9MRP2), CMAC(Sf9BCRP) and 
CMAC(Sf9) columns 
 
750 µg protein were solubilised in 5ml TMEP buffer (50mM Tris-HCl, 50mM 
JO\FHUROP0(*7$P0ȕ-mercaptoethanol, 1:500 protease inhibitor cocktail 
and 1% w/v CHAPS; pH 7.0) for 12h at 4oC. After the solubilisation, the 
membranes were incubated with 100mg IAM-PC stationary phase for 1h at room 
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temperature on an orbital shaker. The membrane-IAM-PC complex was dialysed 
in dialysis buffer (20mM HEPES, 500mM NaCl and 1mM EDTA; pH 8.0) 
overnight at 4OC. Following dialysis, the CMAC stationary phases were packed 
into Tricorn 5/20 columns (GE Healthcare, UK) yielding a 75 mm x 5 mm (i.d) 
chromatographic beds. 
 
7.3.4 Chromatographic studies  
 
The cellular membrane affinity columns were placed in a frontal affinity 
chromatography system and competitive displacement studies were carried out 
using previously described techniques (Moaddel, Wainer 2009).  Briefly the 
system consisted of a manual FPLC injection valve, 50-ml superloop both 
obtained from (Amersham Biotechnology, Columbia, MD), CMAC column, LC-
10AD HPLC pump (Shimadzu Inc.) and an on-line radioactive/scintillation flow 
detector (IN/US, Tampa, FL, USA). Solutions of the marker and test ligands were 
prepared in the running buffer; Tris-HCl [10 mM, pH 7.5] containing 1 mM 
MgCl2, and 5 ml samples were placed in the superloop, pumped across the 
CMAC column at a flow rate of 0.2 ml/min and monitored through a 250 µl flow 
cell with the radioflow detector. The scintillation flow rate was 0.6 ml / min while 
the split ratio was 100. The breakthrough volume of the marker was calculated 
using the retention times at the midpoint of the chromatographic curves and the 
effect on the breakthrough volumes produced by increasing displacer 
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concentrations was used to calculate the dissociation constant (Ki) of the displacer 
as previously described (Moaddel, Wainer 2009). The concentration of the marker 
ligand, [3H]-etoposide, was 1nM, and the concentrations of the displacer ligands 
etoposide and benzbromarone were 10 µM, 25 µM, 50 µM, 100 µM and 250 µM, 
the concentrations of MK571 were 1 µM, 5 µM, 10 µM, 25 µM and 5 0µM, 
furosemide was injected in the concentrations of 1 µM, 2.5 µM, 5 µM, 15 µM and 
30 µM and fumitremorgin C was passed through the column in the concentration 
of 500 nM, 1 µM, 2.5 µM, 5 µM and 10 µM. 
 
 
7.4 Data analysis 
 
Binding affinities, expressed as Ki values, were calculated using non-linear 
regression with a rectangular hyperbolic curve as previously described (Moaddel, 
Wainer 2009), using Prism 4 software (Graph Pad Software Inc., San Diego, CA, 
USA) running on a personal computer.  
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7.5 Results and Discussion 
 
7.5.1. CMAC(Sf9MRP1)  
 
The membranes were immobilized on the IAM stationary phase to create the 
CMAC(Sf9MRP1) and CMAC(Sf9) columns. The binding activity of the 
immobilized MRP1 protein was established using [3H]-etoposide as the marker 
ligand.  This compound, also known as VP-16, has been identified as a substrate 
for the human MRP1 (Bobrowska-Hgerstrand et al. 2007), (Moaddel, Wainer 
2009) and has been previously used in competitive inhibition studies (Gaj et al. 
1998).  When 1 nM [3H]-etoposide was placed in the running buffer, the resulting 
frontal chromatographic trace obtained on the CMAC(Sf9MRP1) column contained 
an initial flat region, followed by a vertical breakthrough and a plateau region, 
Figure 33, Curve A.  These results indicate that the marker bound in a specific 
and saturable manner on the CMAC column (Moaddel, Wainer 2009). The 
addition of 10 µM etoposide produced a significant reduction in the retention 
volume of the marker indicating that the competitive displacement experiments 
could be conducted on the CMAC(Sf9MRP1) column, Figure 33, Curve B. When 
the same experiments were conducted on the CMAC(Sf9) column, a frontal 
chromatographic trace was also observed, Figure. 34, Curve A, indicating that 
[3H]-etoposide also bound specifically and non-specifically to proteins and other 
components of the membranes obtained from the non-transfected Sf9 cells. 
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However, the addition to the mobile phase of up to 100 µM etoposide produced 
no significant reduction in the retention volume of the marker, Figure 34, Curve 
B, indicating that etoposide could be used as a marker for specific competitive 
binding experiments on the CMAC(Sf9MRP1) column. This was consistent with 
previous studies which have demonstrated that specific binding to a target protein 
can be studied in the presence of additional specific and non-specific interactions 
with the cellular membrane by the use of control columns (Moaddel, Wainer 
2009). 
 
Figure 33. Chromatographic traces produced by [3H]-etoposide on the 
CMAC(Sf9MRP1) column, where A = [
3H]-etoposide alone, B = with 10 µM 
etoposide, C = 10 µM (R)-verapamil and D = 10 µM (S)-verapamil. 
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Figure 34. Chromatographic traces produced by (A).[3H]-etoposide 1 nM and 
(B).1nM [3H]-etoposide with 10 µM etoposide on the CMAC(Sf9) column.  
 
 
In order to confirm that specific binding to the MRP1 protein binding could be 
studied on the CMAC(Sf9MRP1) column, the effect of the enantiomers of 
verapamil; (R)-verapamil and (S)-verapamil, on the retention of  [3H]-etoposide 
was determined.  Since (R)-verapamil and (S)-verapamil have equivalent 
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physicochemical properties, any difference in their effect on the retention of [3H]-
etoposide will be due to specific interactions between the immobilized 
membranes and the individual isomers.  
 
Verapamil was also chosen on the basis of the report by Gaj, et al. (Gaj et al. 
1998) which demonstrated that (S)-verapamil was a more efficient MRP1 
inhibitor than (R)-verapamil in human nasopharyngeal KB cell lines over-
expressing MRP1.  In the study by Gaj, et al., 10 µM concentrations of each of 
the verapamil enantiomers were used to determine the changes in the IC50 values 
associated with the anti-proliferative activities of etoposide, vincristine and 
doxorubicin.  In each instance, the presence of (S)-verapamil produced a greater 
decrease in the IC50 value of the anticancer agent than (R)-verapamil. When 
etoposide was the anti-proliferative agent, the observed IC50 was decreased from 
28 µM to 5 µM by (S)-verapamil and to 15 µM by (R)-verapamil, a 3-fold 
difference in enantioselectivity. 
 
In this study, the addition of 10 µM (S)-verapamil to the mobile phase reduced the 
retention time of [3H]-etoposide by 5.4 min, while the equivalent concentration of 
(R)-verapamil reduced the retention by 2.6 min, Figure. 33, Curves C and D, 
respectively, Table 2.  The results indicated that the affinity of (S)-verapamil is 
~2-fold greater than that of (R)-verapamil, which is consistent with the data 
reported by Gaj, et al (Gaj et al. 1998).  Both verapamil enantiomers produced a 
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larger displacement than 10 µM etoposide, which reduced the retention of the 
marker by 0.9 min, Figure 33A, Curve B, Table 2.  This is also consistent with the 
previously reported difference in IC50 values of 48 µM for etoposide (Wong et al. 
2009) and 5 to 13 µM for racemic verapamil (Wong et al. 2009) (Dekkers et al. 
1998). When the same experiments were conducted on the CMAC(Sf9) column, 
no specific displacements of [3H]-etoposide were produced by the compounds 
indicating that the competitive displacements observed on the CMAC(Sf9MRP1) 
column were due to interactions at the expressed MRP1 protein. 
 
Displacer 
Retention time 
(Td) 
(min) 
ǻ7 7R± T(d) 
(min) 
IC50 
(µM) 
etoposide 15.4 0.9 NC 
(R)-verapamil 13.8 2.6 8.6 
(S)-verapamil 11.0 5.4 4.1 
Table 2. The displacement of 1 nM [3H]-etoposide by the addition of 10 µM 
etoposide, (R)-verapamil and (S)-verapamil to the running buffer represented as 
ǻ7FDOFXODWHGDVǻ7= T(o) ± T(d), where T(o) is (15.4 min) the retention time 
of [3H]-etoposide with no displacer in the running buffer and T(d) is the 
retention time of [3H]-etoposide after the addition of the displacer. NC = not 
calculated. 
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IQ D SUHYLRXV VWXG\ XWLOL]LQJ D &0$&Įȕ LW ZDV GHPRQVWUDWHG WKDW UHODWLYH
agonist activities (EC50 values) could be ascertained by a single competitive 
displacement  experiment (Moaddel, Bullock & Wainer 2004).  The experimental 
approach involved the detHUPLQDWLRQRIWKHFKDQJHLQWKHUHWHQWLRQYROXPHǻPO
of a characterized marker ligand produced by the addition of a test compound to 
WKHPRELOHSKDVHZKHUHǻPO UHWHQWLRQYROXPHRIWKHPDUNHUDORQH- retention 
volume of the marker in the presence of the test compound.  When known 
agonists with established EC50 values (standards) were included in the 
experimental set, the relative EC50 values of the test compounds could be 
GHWHUPLQHGIURPWKHUHODWLRQVKLSEHWZHHQǻPO WHVWDQGǻPO (standard). 
 
The relatLRQVKLS EHWZHHQ WKHǻPO DQG(&50 values is based upon the approach 
developed by Cheng and Prusoff (Cheng, Prusoff 1973) in which the functional 
inhibition (IC50 values) of enzymes by competitive inhibitors was equated to the 
binding affinities (Ki values) of these inhibitors.  The analysis can be used to 
determine relative IC50 values between different inhibitors if the inhibitors have 
identical mechanisms of action and the assays are performed under the same 
conditions.  The data obtained in this study was analysed in the same manner in 
order to calculate the relative IC50 values for (S)-verapamil and (R)-verapamil, 
DOWKRXJK WKH FKDQJH LQ UHWHQWLRQ WLPH ǻ7 ZDV XVHG LQ SODFH RI ǻPO  7KH
calculated IC50 values were 4.1 µM and 8.6 µM, respectively. The magnitudes of 
the IC50 values was consistent with the previously reported IC50 value for racemic 
verapamil of 5-7 µM (Dekkers et al. 1998) and 13.4 µM (Wong et al. 2009) and 
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the observation that the inhibitory effect of (S)-verapamil was ~ 2-fold stronger 
than (R)-verapamil was also consistent with the enantioselecitivity reported by 
Gaj, et al (Gaj et al. 1998).  It was of interest to note that the experiments 
conducted by Gaj, et al. involved the inhibition of etoposide transport by 10 µM 
concentrations of the verapamil enantiomers. 
 
The application of the CMAC(Sf9MRP1) column in the determination of binding 
affinities, Ki values, to the immobilized MRP1 protein was confirmed using 
competitive binding experiments in which increasing concentrations of displacer 
ligands were added to the mobile phase and the effects on the retention of the 
marker ligand used to calculate the affinity of the displacer to the immobilized 
protein (Moaddel, Wainer 2009). Increasing concentrations of the MRP1 ligands 
etoposide, benzbromarone and MK571 (Figure 35), produced significant 
reductions in the retention of [3H]-etoposide. 
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Figure 35. Chromatographic traces produced by the displacement of [3H]-
etoposide on the CMAC (Sf9MRP1) column by the addition of MK571, where 
curve A = [3H]-etoposide alone, B = after addition of 1 µM MK571, C = 5µM, D 
=10µM, E = 25 µM, F = 50 µM. 
 
 
The Ki values were calculated and were consistent with previously reported values 
calculated using non-chromatographic methods, Table 3.  The results indicated 
that the CMAC approach could be used to determine binding affinities to the 
MRP1 protein.   
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Table 3. The binding affinities (Ki values) of selected MRP1, MRP2 and BCRP 
ligands calculated from competitive displacement binding studies performed 
using the CMAC(Sf9MRP1), CMAC(Sf9MRP2) and CMAC(Sf9BCRP) columns. See 
text for experimental details. 
 
 
 
 Ki (µM) IC50 (µM) 
CMAC(Sf9MRP1)   
       Etoposide 23.8 ± 6.6 48 (Wong et al. 2009) 
       Benzbromarone 21.0 ± 2,2 4 (Bobrowska-Hagerstrand et al. 
2003) 
       MK571 4.8 ± 1.9 1.2 (Wu et al. 2005) 
CMAC(Sf9MRP2)   
       Etoposide 17.9 + 9.2 48 (Wong et al. 2009) 
       Furosemide 18.0 ± 5.1 24 (Wong et al. 2009) 
CMAC(Sf9BCRP)   
       Etoposide 2.9 ± 1.5 8 (Allen et al. 2003) 
       Fumitremorgin-C 1.7 ± 1.2 3 (Dahan, Amidon 2009) 
166 
 
 
7.5.2 CMAC (Sf9MRP2)  
 
The membranes were immobilized on the IAM stationary phase to create the 
CMAC(Sf9MRP2) column, and when 1 nM [
3H]-etoposide was placed in the 
running buffer the expected frontal chromatographic trace was observed. 
Competitive displacement studies were conducted using etoposide and 
furosemide, a specific MRP2 competitive inhibitor (Wong et al. 2009), (Figure 
36), and the calculated Ki values were consistent with previously reported values 
calculated using non-chromatographic methods, Table 3.  The results indicated 
that the CMAC approach could be used to determine binding affinities to the 
MRP2 protein. 
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Figure 36. Chromatographic traces produced by the displacement of [3H]-
etoposide on the CMAC(Sf9MRP2) column by the addition of etoposide, where 
curve A =  [3H]-etoposide alone, B = after addition of 5 µM etoposide, C 
=10µM, D = 25 µM, E = 50 µM, F = 75 µM. 
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7.5.3 CMAC (Sf9BCRP)  
 
The membranes were immobilized on the IAM stationary phase to create the 
CMAC(Sf9BCRP) column, and when 1 nM [
3H]-etoposide was placed in the 
running buffer the expected frontal chromatographic trace was observed. 
Competitive displacement studies were conducted using etoposide and 
fumitremorgin C, a specific BCRP competitive inhibitor (Rabindran et al. 2000) 
(Figure 37), and the calculated Ki values were consistent with previously reported 
values calculated using non-chromatographic methods, Table 3.  The results 
indicated that the CMAC approach could be used to determine binding affinities 
to the BCRP protein.   
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Figure 37. Chromatographic traces produced by the displacement of [3H]-
etoposide on the CMAC(Sf9BCRP) column by the addition of fumitremorgin-C, 
where curve A =  [3H]-etoposide alone, B = after addition of 500 nM 
fumitremorgin-C , C = 1 µM, D = 2.5 µM, E = 5 µM and   F = 10 µM. 
 
 
The data from this study indicated that membranes from stably transfected Sf9 
cell lines expressing the MRP1, MRP2 or BCRP transporters hae been 
successfully immobilized on the IAM stationary phase to create a series of 
cellular membrane affinity chromatography columns; CMAC(Sf9), 
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CMAC(Sf9MRP1), CMAC(Sf9MRP2) and CMAC(Sf9BCRP). The results 
demonstrated that the resultant columns could be used to study the interactions of 
small molecules with the expressed transporters and to determine Ki values, 
relative IC50 values and enantioselectivities.  The successful development and 
characterization of the Sf9 columns represented the first CMAC columns 
produced using membranes obtained from an insect cell line.  Since the Sf9 and 
related insect cell lines are popular and highly productive expression systems, 
these results represent a potential expansion of the CMAC approach. 
 
The CMAC(Sf9) columns produced in this study were stable for up to one month 
and could be used for ~100 samples during this period.  As has been previously 
discussed, there was no attempt to purify the immobilized membranes and the 
amount of immobilized protein on the column, and thereby the column to column 
reproducibility, was determined using the number of active binding sites, Bmax 
(Moaddel, Wainer 2009). The calculated Bmax values had less than 10% variation 
between columns for the two CMAC (Sf9MRP1) columns, indicating that the 
columns can be reproduced.  
 
Currently, there are several approaches that are used to screen substrates / 
inhibitors for interactions with Pgp, MRP1, MRP2 and BCRP. MRP1 transport, 
for example, has been studied using isolated membrane vesicles (Renes et al. 
1999), (Renes et al. 2000) inside-out vesicles (Wu et al. 2005), substrate toxicity 
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(Dahan, Amidon 2009) and intracellular accumulation of transported substrate 
(Wong et al. 2009). Similar studies with membrane vesicles (Smeets et al. 2004) 
and inside-out vesicles (Zimmermann et al. 2008) were also carried out for the 
MRP2 and BCRP transporters (Lagas et al. 2008). Thus most of the standard 
methods employed to screen compounds involve culture of native or transfected 
cells and isolation of membranes. 
 
The data from this study indicated that the CMAC columns produced and 
characterized in this study represent a potential alternative approach to the 
screening of compounds for their binding to and activity at MRP1, MRP2 and 
BCRP.  However, while the average time needed for the frontal experiment was 
25 min, the average washout period was 2 h, which limited the potential use of 
these columns in large screening programs.   It had previously demonstrated that 
CMAC-based screening is hampered by the long washout periods required with 
the IAM stationary phase and that this problem can be overcome by moving to an 
open tubular chromatographic format (Moaddel, Bullock & Wainer 2004). This is 
illustrated by the studies with the CMAC(Pgp) columns in which moving to an 
open tubular format  reduced the total time required for the frontal experiment and 
washout to 30 min and resulted in a throughput that was equivalent to the rate 
obtained with the Caco-2 screen (Moaddel et al. 2006).  The demonstration that 
the Sf9 membranes used in this study can be immobilized on the IAM support to 
create functional CMAC(Sf9MRP1), CMAC(Sf9MRP2) and CMAC(Sf9BCRP) 
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columns suggested that these membranes can also be immobilized in the open 
tubular format. 
 
 
7.6 Conclusion 
 
The data from this study indicated that membranes from insect cell lines like the 
Sf9, expressing a target protein can be immobilized on an IAM (immobilized 
artificial membrane) stationary phase. The resultant columns could be used to 
study the interactions of target proteins with specific ligands using displacement 
frontal chromatography. Binding affinities so calculated have been shown to 
correlate well with reported literature values calculated using cell based assay 
systems. Moreover the CMAC(Sf9MRP1), CMAC(Sf9MRP2), CMAC(Sf9BCRP) and 
the CMAC(Sf9)  columns reported in this study can be constructed in 48 hours as 
the cellular membranes are commercially available with the target protein 
expressed. The columns are fairly easy to assemble, reproducible and efficient. 
The CMAC columns reported here are an initial step in the development of 
screens for lead candidates as these efflux proteins play a crucial role in oral drug 
bioavailability and drug-drug interactions. The functional over-expression of 
MRP1, MRP2 and BCRP in neoplastic tumours also makes these screens essential 
in the development of anticancer agents. 
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8. Analysis of ABC transporters in clinical specimens 
 
8.1. Introduction 
 
Having confirmed the presence, localization and functionality of Pgp, MRP1, 
MRP2 and BCRP in the GBM and astrocytoma cell lines; the final step of the 
research programme was to investigate the clinical implications of the above-
mentioned findings. Literature suggests strong evidence of expression profiles of 
ABC transporters in various tissues (Warren et al. 2009). Considerable work has 
been done as regards as investigating the clinical significance of the presence of 
ABC transporters (Dauchy et al. 2009) but definitive evidence of nuclear 
expression profile is hardly found. 
 
8.2. Aims and objectives 
 
In order to investigate the expression of ABC transporters in clinical specimens, 
healthy brain and GBM autopsy specimens were analysed for Pgp, MRP1, and 
BCRP by western blot analyses. Immunohistochemistry was used to gain a better 
understanding of the localization of the BCRP in both healthy brain and GBM 
autopsy and biopsy specimens. 
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8.3. Materials and Methods 
 
8.3.1 Preparation of whole tissue lysates 
 
100 mg of tissue was lysed on ice for 20 min in Tris-HCl [10 mM, pH 7.4] 
containing 0.15 M NaCl, 5mM EDTA, 1% v/v Triton X-100, 1:500 dilution of a 
stock solution of protease inhibitor cocktail, 0.1M sodium ortho-vanadate and 
0.1M DTT (Sigma Aldrich, St-Louis, MO, USA). Insoluble material was removed 
by centrifugation (17,000!g for 20 min at 4oC) and the supernatant was collected 
and stored at -80oC until further analysis. 
 
8.3.2 Western Blot analysis 
 
Western blotting is an analytical technique used to detect a specific protein in an 
extract or a lysate. The protein of interest is separated by gel electrophoresis by 
the length of the polypeptide. Once separated, the protein is then transferred to a 
nitrocellulose or PVDF (poly-vinyl difluoride) membrane, where they are probed 
by antibodies specific to the target antigen. In the study described in this chapter, 
the protein concentration of the lysates was measured with the BCA protein assay 
kit (Thermo Scientific, Waltham, MA, USA) using BSA (bovine serum albumin) 
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as standard. An equal amount of 3X Laemlli sample buffer (Laemmli 1970) was 
added, and the samples (70 µg) were separated by electrophoresis using precast 4-
12% gradient SDS-polyacrylamide gels (Invitrogen, Carlsbad, CA, USA) and 
transferred to polyvinylidene difluoride membranes using iBLOT (Invitrogen). 
The membranes were blocked with 5% v/v dry non-fat milk in Tris-buffered 
saline with 0.1% v/v Tween-20 and then probed with mouse monoclonal anti-Pgp 
(clone C219, 1:500 dilution; Alexis Biochemicals, Plymouth Meeting, PA, USA), 
rat monoclonal anti-MRP1 (clone MRPr1, 1:500 dilution, Alexis Biochemicals), 
mouse monoclonal anti-BCRP (clone BXP-21, 1:500 dilution; Alexis 
Biochemicals) and mouse monoclonal anti-ȕ-actin (clone AC-15, 1:5000 dilution; 
Abcam, Cambridge, MA, USA). This was followed by appropriate horseradish 
peroxidase-conjugated secondary antibodies; ECL Anti-mouse IgG (1:5000 
dilution; GE Healthcare, Piscataway, NJ, USA) in the case of Pgp, %&53DQGȕ-
Actin. MRP1 blots were incubated with ECL Anti-rat IgG (1:5000 dilution; GE 
Healthcare). The ECL Western blotting detection system (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was used for visualization. 
 
8.3.3 Immunohistochemistry 
 
Immuno-histochemical staining was carried out using an established avidin-biotin 
complex indirect immune-peroxidase method as described (Bain, McLachlan & 
LeBlanc 1997), (van Tellingen et al. 2003). Routine biopsy specimens were 
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retrospectively obtained from the Department of Pathology at Cooper University 
Hospital Institutional Review Board. The specimens were cryostat sectioned at 7 
µm onto poly-L-lysine coated slides, air-dried and stored at -70oC. Immuno-
histochemical stains were performed on a fully automated Benchmark Ultra IHC 
stainer (Ventana Medical Systems, Tuscon, AZ, USA) to visualize BCRP using 
the mouse monoclonal anti-BCRP (clone BXP-21, 1:100 dilution) 
 
8.4 Results and Discussion 
 
The aim of this study was to confirm the expression profile of Pgp, MRP1 and 
BCRP in human healthy brain and GBM autopsy tissue specimens. Owing to the 
large variation in the size of the target proteins in this study, a 4-12 % gradient 
poly-acrylamide gel was chosen for the electrophoretic separation. The anti-Pgp 
C219 clone has been shown to detect a 170 kDa band (Weber, Eckert & Mller 
2006), (Ambroziak et al. 2010) which corresponds to Pgp. The anti-MRP1, 
MRPr1 clone detects a band of 190 kDa (Calatozzolo et al. 2005), (Rajagopal, 
Simon 2003). The BXP-21 clone was used to detect the BCRP band at 72 kDa as 
shown by Maliepaard et al. (Maliepaard et al. 2001b). Significant and uniform 
levels of Pgp and MRP1 were observed in the healthy brain specimens as   
indicated in Figure 38 A. While BCRP was expressed in all six specimens, 
variation was observed in half the population. Equal loading of protein was 
HQVXUHG E\ QRUPDOL]LQJ WR ȕ-actin. The reverse trend was observed in the 
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immunoblots of the GBM tissue specimens in Figure 38 B. Expression of Pgp and 
MRP1 was inconsistent among the six samples, whereas BCRP was presence in a 
uniform manner.  
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Figure 38. Western Blot analysis of ABC transporters in healthy and WHO 
Grade IV Glioblastoma multiforme autopsy specimens. (A) Expression of Pgp, 
MRP1, MRP2 and BCRP in healthy brain autopsy specimens, (B) Expression 
of Pgp, MRP1, MRP2 and BCRP in WHO Grade IV Glioblastoma multiforme 
brain autopsy specimens. 
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The next stage of this study was to investigate the expression pattern of BCRP in 
autopsy and biopsy brain specimens by immunohistochemistry. Other groups 
have investigated the expression of BCRP in various tissues and indicated 
subcellular localization of BCRP. The study of Diestra et al. (Diestra et al. 2002) 
clearly showed that BCRP is expressed in 129 out of 150 tumour samples 
including 5 out of 5 GBM tissue specimens. More recently, BCRP has been 
shown to be localised only in microvessel endothelium of human control brain 
(Aronica et al. 2005). The results from this immuno-histochemical study indicated 
that BCRP was indeed expressed in microvessel endothelium and in the 
extranuclear compartment of glial cells in a human control brain tissue biopsy 
(Figure 39A). When tissue from a human breast tumour biopsy specimen was 
examined, a marked staining of BCRP was observed in the 
cytosolic/membraneous compartment, but no nuclear staining was found (Figure 
39B). Immuno-histochemical staining of a tissue biopsy sample from a human 
GBM tumour indicated the presence of BCRP in the extra-nuclear compartment 
and, most importantly, nuclear BCRP expression was observed in a subpopulation 
of tumour cells (Figure 39C). 
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Figure 39. Expression and localisation of BCRP in human brain tumour biopsy 
and autopsy specimens. Immunohistochemistry analysis of BCRP in (A) 
Healthy specimen number 1227 with staining of brain endothelial cells 
(denoted as *) and significant cytoplasmic expression without nuclear 
expression of BCRP in brain glial cells; (B) breast cancer specimen showing 
significant cytoplasmic expression and no nuclear expression of BCRP; (C) 
Biopsy GBM specimen and (D) autopsy GBM specimen number 1786 showing 
significant cytoplasmic and nuclear expression of BCRP. (E) Biopsy GBM 
specimen at low (200X) and high (400X) magnification (inset) demonstrating 
nuclear BCRP staining in a subpopulation of cells. Arrows denote nuclear 
staining of BCRP. 
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8.5. Conclusion 
 
Presence of Pgp, MRP1 and BCRP in healthy brain tissue and observed up-
regulation of BCRP in the GBM tissue specimens corroborates with the findings 
from the cellular studies. Significant presence of BCRP in the GBM autopsy 
specimens as confirmed by western blotting might indicate a key role in drug 
resistance. Nuclear expression of BCRP in GBM cells, which was reported in 
Chapters 4 and 5, was confirmed in select tissue specimens. GBM autopsy 
specimens indicated a strong presence of BCRP both in cytoplasm and nucleus. 
These findings indicate the importance of BCRP as a target at the nuclear level for 
drug resistant GBM. 
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Chapter 9 
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9.  Conclusion and suggestion for future work 
  
Effective chemotherapy of GBM is limited due to a multitude of factors. Many 
anticancer agents fail to cross the blood brain barrier (BBB) as they are not 
lipophilic and those that do penetrate the BBB are often effluxed by ABC 
transporters such as Pgp, MRP1, MRP2 and BCRP. One clinical strategy to 
overcome transporter-mediated MDR is to co-administer ABC transporter 
inhibitors with the objective of increasing intracellular concentrations of the 
chemotherapeutic agents and achieving required therapeutic exposure. This 
approach is predicated on the assumption that ABC transporter proteins are 
located primarily on cellular membranes and that the primary goal is to increase 
the cytosolic concentrations of the cytotoxic agents. However, the data from this 
research programme suggest that overcoming a BCRP-related MDR phenotype 
may be a more complex task. In this study, it was demonstrated the presence of 
BCRP in the nuclear extracts of a number of human derived glioblastoma and 
astrocytoma cell lines. This finding is consistent with previous reports showing 
that BCRP can be found in intracellular compartments, such as the mitochondria 
(Takada et al. 2005) and the perinuclear region (Lemos et al. 2009). In this 
research programme it was reported for the first time that BCRP being localises 
specifically to the nucleus of GBM cells. In-silico analysis of human BCRP 
protein sequence (Swiss-Prot entry: Q9UNQ0) indicated the presence of a cluster 
of four lysine residues at position 357±360. This motif (357KKKK360), present 
in all three BCRP variants, has been identified as a putative nuclear localisation 
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sequence (NLS), which tags a protein for nuclear import through interaction with 
specific receptors at nuclear pores (Nardozzi, Lott & Cingolani 2010). 
Interestingly, BCRP is the target of phosphorylation at Thr362 by Pim-1 kinase 
(Xie et al. 2008), which could have a profound impact on its cellular 
redistribution. Moreover, the protein Ser/Thr kinase, Akt, regulates the cell 
surface expression of BCRP by promoting its phosphorylation (Takada et al. 
2005). Whether nuclear BCRP import is dependent of the phosphorylation on 
Thr362 is unclear. Alternatively, phosphorylation of a yet unknown putative site 
may upregulate importin-dependent BCRP nuclear import. Such phosphorylation 
may elicit conformational change within BCRP to enable better or reduced access 
to the nuclear import machinery. It is tempting to speculate that nuclear import of 
BCRP could be mediated, at least in part, through cell type- or region-specific 
activation of a discrete pool of kinase(s) acting on BCRP. The data from the 
immuno-histochemical studies of human tissue biopsies indicate that the nuclear 
expression of BCRP is a clinically relevant issue. The results also shed some light 
on the mechanisms associated with the development of the ABC transporter-
associated MDR phenotype. In a recent review, Moitra and co-workers (Moitra, 
Lou & Dean 2011) present four potential models of this phenomenon: (i) 
conventional model in which a population of the tumour cells have the MDR 
phenotype before initiation of chemotherapy; (ii) cancer stem cell model in which 
a small population of tumour stem cells express the MDR phenotype before 
chemotherapy; (iii) acquired-resistance stem cell model in which chemotherapy 
induces genetic changes that produce the MDR phenotype; (iv) intrinsic resistance 
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model in which the tumour has intrinsic resistance to chemotherapy. The 
identification of BCRP nuclear expression in a subpopulation of tumour cells in a 
human GBM biopsy specimen supports the first two models. It is believed that the 
nuclear expression of BCRP has functional consequences with regard to the 
removal of cytotoxic drugs from the nucleus. Variants of BCRP have been shown 
to respond differentially to its substrates (Kondo et al. 2004), and, therefore, 
discrete variations in BCRP transcript sequences may contribute to cell type 
specific differences in WKHPDJQLWXGHRI%&53¶VH[SRUWfunction (Ni et al. 2010). 
Moreover, the presence of Pgp on the nuclear membrane indicates that removal of 
MTX from the nucleus is presumably mediated by nuclear BCRP (this study), 
Pgp (Baldini et al. 1995) or other proteins involved in the nuclear cytoplasmic 
trafficking and compartmentalisation of drugs. In conclusion, the expression of 
BCRP in the nuclei of glioblastoma and astrocytoma cell lines represents a 
potentially new mechanism of MDR. Insertion of BCRP within the nuclear 
envelope may alter the conformation and/or function of the protein as well as the 
efficacy of chemotherapeutic drugs relative to the transporter located at the 
plasma membrane. Interaction with the various components of cellular 
membranes has been suggested as the source RI IXQFWLRQDO GLIIHUHQFHV LQ ȕ
adrenergic receptors expressed in different cell lines (Audet, Bouvier 2008). The 
presence of BCRP and other ABC transporters on the nuclear membrane poses 
new therapeutic challenges in the treatment of MDR tumours and indicate that the 
development of specific inhibitors of nuclear ABC transporters may be required. 
Indeed the substrate and inhibitor overlap among the ABC transporters poses 
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additional problem. There are hardly if any definitive screening techniques which 
can aid in defining selective ABC transporter inhibitors. The immobilization of 
Sf9 insect cells expressing Pgp, MRP1, MRP2 and BCRP proteins was a step in 
this direction. These stationary phases were shown to successfully identify 
receptor specific substrates and inhibitors and open new avenues for screening of 
larger libraries of test compounds.  
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